



(51) International Patent Classification:

A61K 9/52 (2006.01) A61K 31/192 (2006.01)  
A61K 47/44 (2006.01) A61K 31/196 (2006.01)  
A61P 25/00 (2006.01) A61K 31/21 (2006.01)  
A61K 31/145 (2006.01) A61K 31/60 (2006.01)  
A61K 31/19 (2006.01)

100 Clearwater Dr., Unit 147, Falmouth, ME 04105 (US).  
**FATMI, Aqeel, A.;** 4125 Premier Drive, High Point, NC 27265 (US).

(74) Agent: **BROWN, Bernard A.;** Womble Carlyle Sandridge & Rice, LLP, One West Fourth Street, Winston-Salem, NC 27101 (US).

(21) International Application Number:

PCT/US2015/017893

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

27 February 2015 (27.02.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/946,233 28 February 2014 (28.02.2014) US  
61/950,648 10 March 2014 (10.03.2014) US  
62/011,604 13 June 2014 (13.06.2014) US  
62/061,185 8 October 2014 (08.10.2014) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(71) Applicant: **BANNER LIFE SCIENCES LLC** [US/US];  
4125 Premier Drive, High Point, NC 27265 (US).

(72) Inventors: **DYAKONOV, Tatyana;** 7 Indigo Lake Terrace, Greensboro, NC 27455 (US). **AGNIHOTRI, Sunil;**

[Continued on next page]

(54) Title: CONTROLLED RELEASE ENTERIC SOFT CAPSULES OF FUMARATE ESTERS




FIGURE 7

(57) Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release enteric soft capsules and matrices comprising fumarate esters are described.

WO 2015/130998 A1

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *as to the applicant's entitlement to claim the priority of*  
GW, KM, ML, MR, NE, SN, TD, TG). *the earlier application (Rule 4.17(iii))*

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted*  
*a patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*

**CONTROLLED RELEASE ENTERIC SOFT CAPSULES OF FUMARATE ESTERS****CROSS REFERENCE TO RELATED APPLICATIONS**

This application claims priority to U.S. Provisional Patent Application Nos. US  
5 61/946,233, filed on February 28, 2014; US 61/950,648, filed on March 10, 2014; US  
62/011,604, filed on June 13, 2014, and US 62/061,185, filed on October 8, 2014, each of which  
are incorporated by reference herein in their entirety. This application is related to U.S. Patent  
Application No. 14/633,164 filed on February 27, 2015, which is incorporated by reference  
herein in its entirety.

10

**TECHNICAL FIELD**

Described herein are pharmaceutical compositions comprising fumarate esters, methods  
for making the same, and methods for treating subjects in need thereof. In particular, oral  
pharmaceutical compositions comprising controlled release enteric soft capsules and matrices  
15 comprising fumarate esters are described.

**BACKGROUND**

Fumaric acid esters (FAE; fumarate esters, e.g., dialkyl fumarate esters such as dimethyl  
fumarate or monomethyl fumarate) are pharmacologically active substances used for treating  
20 hyperproliferative, inflammatory, or autoimmune disorders. They were first used to treat  
psoriasis and were licensed for this indication in Germany in 1995 as Fumaderm<sup>®</sup> (Biogen Idec,  
Inc., Cambridge, MA, USA). Fumaderm<sup>®</sup> produces various undesirable side effects, including  
flushing, headaches, dizziness, eructation, nausea, vomiting, abdominal and intestinal cramps,  
and diarrhea. High concentrations of the drug released in the stomach are believed to be  
25 responsible for such side effects.

After oral intake, the main component of Fumaderm<sup>®</sup>, dimethyl fumarate (DMF), is  
hydrolysed by esterases to monomethyl fumarate (MMF), the bioactive metabolite. After  
absorption in the small intestine, MMF is believed to interact with immunocytes in the  
bloodstream. The primary plasma metabolites of DMF are monomethyl fumarate, fumaric acid,  
30 citric acid, and glucose. Monomethyl fumarate is further metabolized in the tricarboxylic acid  
cycle to carbon dioxide and water.

An improved oral formulation of the FAE BG-12 active ingredient (i.e., DMF) was developed and approved for the treatment of multiple sclerosis. This formulation, TECFIDERA<sup>®</sup> (Biogen Idec, Inc.), is available as hard gelatin delayed-release capsules containing 120 mg or 240 mg of granulated dimethyl fumarate enterically coated minitables.  
5 See International Patent Application Publication No. WO 2013/119677 and U.S. Patent No. 6,509,376, which are incorporated by reference herein for such teachings. TECFIDERA<sup>®</sup> was intended to reduce the undesirable side effects by preventing release of DMF in the stomach.

The enterically coated DMF granules in TECFIDERA<sup>®</sup>, however, lack uniformity in shape and size, and the enteric coating may not be evenly distributed over the minitables. This  
10 lack of homogeneity can diminish the enteric properties and affect the acid-resistance, dissolution, and release rates. In addition, the integrity of the acid-resistant coating fails when the coating cracks or flakes off. This leads to DMF release in the stomach and can cause flushing and the negative gastrointestinal side effects.

A subject's stomach content also affects delivery of DMF from TECFIDERA<sup>®</sup>. A meal  
15 was shown to decrease  $C_{\max}$  by 40% and delay  $T_{\max}$  from 2.0 hours to 5.5 hours; the AUC was unaffected. See WO 2006/037342, which is incorporated by reference herein for such teachings. This was shown to reduce the incidence of flushing by approximately 25% in the postprandial state. See TECFIDERA<sup>®</sup> Prescribing Information 03/2013 (Biogen Idec Inc.), which is incorporated by reference herein for such teachings.

In addition, DMF sublimates at relatively low temperatures. About 15–20% of the DMF  
20 active ingredient is lost owing to sublimation during the wet-granulation processing used for manufacturing TECFIDERA<sup>®</sup>. See WO 2013/076216, which is incorporated by reference herein for such teachings. Sublimation also causes loss of DMF during storage and unused TECFIDERA<sup>®</sup> capsules must be discarded 90 days after a bottle of the capsules is opened.

Accordingly, it is desirable to develop oral controlled release formulations of fumarate  
25 esters: (1) that prevent flushing and the undesirable GI side effects associated with oral administration of fumarate esters; (2) that reduce or eliminate fumarate ester sublimation during manufacturing and storage; (3) that increase the long-term stability of the pharmaceutical composition; and (4) that provide a variety of different release profiles, dosage forms, and dosing  
30 regimens.

**SUMMARY**

Described herein are controlled release pharmaceutical compositions comprising fumarate esters suspended in a lipid or lipophilic matrix. The pharmaceutical composition is encapsulated in an enteric soft capsule. The oral enteric soft capsules comprising controlled release matrix compositions prevent release of the fumarate ester active ingredient in the gastric environment, but release the active ingredient in the intestine in a controlled manner. The compositions can be tailored to provide immediate release, controlled release, delayed release, or extended release pharmacokinetics by the composition of the matrix fill. The formulations described herein comprise solid micronized particles of fumarate esters suspended in a matrix. The controlled release enteric capsule comprising a matrix of fumarate esters are predicted to reduce, ameliorate, or eliminate the undesirable gastrointestinal side effects observed with prior fumarate ester pharmaceuticals. Further, the formulations preclude or reduce sublimation of the fumarate ester during manufacturing and storage.

One embodiment described herein is an oral pharmaceutical composition comprising a controlled release composition of a fumarate ester, including, but not limited to, dimethyl fumarate (DMF) or monomethyl fumarate (MMF). In one embodiment, the pharmaceutical composition comprises a controlled release enteric soft capsule and matrix comprising a fumarate ester. In one aspect, the matrix comprises a lipid or lipophilic vehicle, a neutralizing agent, and solid particles of fumarate esters. In another aspect, the matrix comprises a lipid or lipophilic vehicle, a neutralizing agent, excipients, and solid particles of a fumarate ester. In another aspect, the matrix comprises a lipid or lipophilic vehicle, a neutralizing agent, surfactants, and solid particles of a fumarate ester. In one aspect, the lipid or lipophilic vehicle comprises polyvinylpyrrolidones, mono- and di-glycerides, and oils. In another aspect, the surfactant can comprise polysorbate 80 or polyoxyl 40 hydrogenated castor oil. In another aspect, the solid particles of fumarate ester comprise milled or micronized particles. In another aspect, the milled or micronized particles of fumarate ester comprise average particle distribution sizes of about 20  $\mu\text{m}$  to about 300  $\mu\text{m}$ , including each integer within the specified range. In another aspect, the solid particles of fumarate esters comprise average particle distribution sizes of about 70  $\mu\text{m}$  to about 260  $\mu\text{m}$ , including each integer within the specified range. In another aspect, the solid microparticles of fumarate esters have average particle distribution sizes of about 68  $\mu\text{m}$ . In another aspect, the solid particles of fumarate esters have average particle

distribution sizes of about 260  $\mu\text{m}$ . In another aspect, the neutralizing agent comprises an organic acid, ester, or salt. In another aspect, the neutralizing agent comprises at least one of lactate, fumarate, caprylate, caprate, oleate, maleate, succinate, tartrate, citrate, glutamate, gluconate, or esters or salts thereof, or combinations thereof. In another aspect, the matrix  
5 comprises a fumarate ester, a mixture of mono- and di-glycerides, polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid.

In another embodiment, the pharmaceutical composition comprises a matrix fill comprising about 28–32% by weight of fumarate ester (PSD 80  $\mu\text{m}$ ); about 50–54% of a mixture of mono- and di-glycerides; at least about 1–10% polyvinylpyrrolidone; at least about 1–10%  
10 polyoxyl 40 hydrogenated castor oil, and at least about 1–5% lactic acid. In one aspect, the composition has controlled release, delayed release, or extended release properties. In another aspect, the composition further comprises one or more non-steroidal anti-inflammatory drugs (NSAIDs). In one aspect, the composition prevents sublimation of the fumarate ester during manufacturing. In another aspect, the composition prophylactically reduces the onset or  
15 ameliorates the symptoms of any flushing side effects. In another aspect, the composition reduces the onset or ameliorates the severity of any gastrointestinal side effects. In another aspect, the composition is stable for at least 1 year at conditions comprising 25 °C, 60% relative humidity. In another aspect, the composition is stable for at least 2 years at conditions comprising 25 °C, 60% relative humidity.

20 In one embodiment, the enteric soft capsule shell comprises one or more enteric, acid-insoluble polymers, a film-forming polymer, a plasticizer, an alkali-neutralizing agent, a solvent, and optionally, a coloring agent, a flavoring, or a pharmaceutical excipient.

In another embodiment, the enteric soft capsule shell comprises about 30% of at least one film-forming polymer; about 10% of at least one enteric, acid-insoluble polymer; about 20% at  
25 least one plasticizer; about 1% of at least one alkali-neutralizing agent; about 37% of a solvent; and about 1.5% of an opacifying agent. In one aspect, the enteric soft capsule shell comprises gelatin, acrylic methacrylate copolymers, glycerol, triethyl citrate, ammonia, water, and titanium dioxide.

Another embodiment described herein is a method for manufacturing an oral enteric soft  
30 capsule shell and matrix comprising a fumarate ester, the method comprising: (i) providing a matrix fill comprising any of the composition described herein; (ii) providing an enteric soft

capsule shell comprising any of the composition described herein; (iii) casting the enteric soft capsule shell into films using heat-controlled drums or surfaces; and (iv) forming an enteric soft capsule comprising the matrix fill composition using rotary die encapsulation technology. In one aspect, an enteric soft capsule comprising a fumarate ester matrix produced by said method.

5 Another embodiment described herein is an enteric soft capsule comprising a fumarate ester matrix, wherein the matrix comprises: about 28–32% fumarate ester (PSD: 80  $\mu\text{m}$ ); about 50–54% mono- and di-glycerides; at least about 1–7% polyvinylpyrrolidone; at least about 2–10% polyoxyl 40 hydrogenated castor oil, and at least about 1–5% lactic acid; and wherein the enteric soft capsule shell comprises: about 30% gelatin; about 10% methylacrylic acid  
10 copolymer; about 18% glycerol; about 1 % triethyl citrate; about 1.5% ammonia; about 37% water; and about 1.5% titanium dioxide.

In one aspect, the enteric soft capsule comprising a fumarate ester is resistant to dissolution at about pH 1.2 for at least about 2 hours. In another aspect, the enteric soft capsule comprising a fumarate ester begins dissolution at pH of about 6.8 within about 10 min. In one  
15 aspect, the enteric soft capsule has immediate release, controlled release, delayed release, or extended release properties. In another aspect, the enteric soft capsule comprising a fumarate ester reduces the onset or ameliorates the severity of any flushing or gastrointestinal side effects.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of multiple  
20 sclerosis or psoriasis, comprising administering to a subject in need thereof an oral pharmaceutical composition comprising a controlled release enteric soft capsule and matrix comprising fumarate ester. In one aspect, the pharmaceutical composition comprises a controlled release enteric soft capsule comprising a formulation of fumarate ester.

Another embodiment described herein is an oral pharmaceutical composition as described  
25 herein that is useful for treating neurodegenerative disorders. In one aspect, the pharmaceutical composition is useful for treating multiple sclerosis or psoriasis. In one embodiment described herein, subjects that are administered the oral pharmaceutical composition as described herein exhibit a mean plasma monomethyl fumarate  $T_{\text{max}}$  of from about 1.5 hours to about 3.5 hours.

Another embodiment described herein is a pharmaceutical composition comprising a  
30 controlled release composition comprising a formulation of a fumarate ester useful for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing

the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to, acute dermatitis, adrenal leukodystrophy, AGE-induced genome damage, Alexander's disease, alopecia areata (totalis and universalis), Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, arthritis, asthma, autoimmune diseases, balo concentric sclerosis, Behçet's syndrome, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular insufficiency, central nervous system vasculitis, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic active (lupoid) hepatitis, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease and cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, diabetic retinopathy, fibromyalgia, graft versus host disease, granuloma annulare, granulomas including annulare, Grave's disease, Hashimoto's thyroiditis, hepatitis C viral infection, herpes simplex viral infection, human immunodeficiency viral infection, Huntington's disease, inflammatory bowel disease, irritable bowel disorder, ischemia, juvenile-onset diabetes mellitus, Krabbe disease, lichen planus, macular degeneration, mitochondrial encephalomyopathy, monomelic amyotrophy, multiple sclerosis (MS), myocardial infarction, necrobiosis lipoidica, neurodegeneration with brain iron accumulation, neurodermatitis, neuromyelitis optica, neuropathic pain, neurosarcoidosis, NF- $\kappa$ B mediated diseases, optic neuritis, organ transplantation rejection, paraneoplastic syndromes, Parkinson's disease, Pelizaeus-Merzbacher disease, pemphigus, pernicious anemia, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, radicular pain, radiculopathic pain, reperfusion injury, retinopathic pigmentosa, rheumatoid arthritis (RA), sarcoidosis, sarcoidosis, Schilder's disease, sciatic pain, sciatica, Sjögren's syndrome, subacute necrotizing myelopathy, such as polyarthritis, Susac's syndrome, systemic lupus erythematosus (SLE), tumors, transverse myelitis, ulcerative colitis, or Zellweger syndrome.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to, acute dermatitis, adrenal leukodystrophy, AGE-induced genome damage, Alexander's disease, alopecia areata (totalis and universalis), Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, arthritis, asthma, autoimmune diseases, balo concentric sclerosis, Behçet's syndrome, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular



insufficiency, central nervous system vasculitis, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic active (lupoid) hepatitis, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease and cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, diabetic retinopathy, fibromyalgia, graft versus host disease, granuloma annulare, granulomas including annulare, Grave's disease, Hashimoto's thyroiditis, hepatitis C viral infection, herpes simplex viral infection, human immunodeficiency viral infection, Huntington's disease, inflammatory bowel disease, irritable bowel disorder, ischemia, juvenile-onset diabetes mellitus, Krabbe disease, lichen planus, macular degeneration, mitochondrial encephalomyopathy, monomelic amyotrophy, multiple sclerosis (MS), myocardial infarction, necrobiosis lipoidica, neurodegeneration with brain iron accumulation, neurodermatitis, neuromyelitis optica, neuropathic pain, neurosarcoidosis, NF- $\kappa$ B mediated diseases, optic neuritis, organ transplantation rejection, paraneoplastic syndromes, Parkinson's disease, Pelizaeus-Merzbacher disease, pemphigus, pernicious anemia, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, radicular pain, radiculopathic pain, reperfusion injury, retinopathic pigmentosa, rheumatoid arthritis (RA), sarcoidosis, Schilder's disease, sciatic pain, sciatica, Sjögren's syndrome, subacute necrotizing myelopathy, such as polyarthritis, Susac's syndrome, systemic lupus erythematosus (SLE), tumors, transverse myelitis, ulcerative colitis, or Zellweger syndrome comprising administering to a subject in need thereof an oral pharmaceutical composition comprising a controlled release formulation comprising a fumarate ester. In one embodiment described herein, the oral pharmaceutical composition comprises an enteric soft capsule and matrix comprising a fumarate ester. In one aspect, the pharmaceutical composition comprises a controlled release enteric soft capsule comprising a formulation of a fumarate ester. In another aspect, the pharmaceutical composition is an immediate release, delayed release, controlled release, or extended release formulation of a fumarate ester.

Another embodiment described herein is an oral pharmaceutical composition comprising an immediate release, delayed release, controlled release, or extended release formulation of a fumarate ester. In one aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit one or more pharmacokinetic parameters selected from the group consisting

of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 2.41 mg/L and (b) a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 4.81 h·mg/L to about 11.2 h·mg/L. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 3.4 mg/L, (b) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 5.5 h·mg/L, and (c) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 5.6 h·mg/L. In another aspect, the fumarate ester formulation is encapsulated in an enteric soft capsule. In another aspect, the capsule contains a total amount of about 240 mg of a fumarate ester, wherein subjects administered the capsule exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 3.5 hours; (b) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 3.4 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 5.5 h·mg/L; and (d) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 5.6 h·mg/L.

Another embodiment described herein is a once daily oral pharmaceutical composition comprising a delayed release, controlled release, or extended release formulation of a fumarate ester. In one aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 5.2 mg/L and (b) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 5.2 mg/L, (b) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 13.5 h·mg/L, and (c) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L. In another aspect, the fumarate ester formulation is encapsulated in an enteric soft capsule. In another aspect, the capsule contains a total amount of about 480 mg of a fumarate ester, wherein

subjects administered the capsule once daily exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 10.5 hours; (b) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 5.2 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 13.5 h·mg/L; and (d) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the compositions described herein and a therapeutically amount of one or more non-steroidal anti-inflammatory drugs effective to reduce flushing. In one aspect, the one or more non-steroidal anti-inflammatory drug is aspirin, ibuprofen, naproxene, diclofenac, ketoprofen, celecoxib, or a combination thereof.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising administering to a subject in need thereof any one of the compositions described herein containing a compound, or a pharmaceutically acceptable salt thereof, that metabolizes to monomethyl fumarate wherein said administering the composition provides one or more of the following pharmacokinetic parameters: (a) a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 10.5 hours; (b) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 5.2 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 4.81 h·mg/L to about 15.2 h·mg/L; (d) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 13.5 h·mg/L; and (e) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L.

Another embodiment described herein is a pharmaceutical composition comprising any one of the pharmaceutical compositions described herein for administration to a subject having multiple sclerosis, comprising a therapeutically effective amount of one or more fumarate esters, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing,

abdominal pain, diarrhea, and nausea in the subject. In one aspect, the subject experiences one or more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%. In another aspect, the subject is a child. In one aspect, the child is over 9.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, the method comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any one of the pharmaceutical compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 to a subject in need thereof, wherein the subject achieves a reduction of annualized relapse rate relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea. In one aspect, the subject experiences one or more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%. In another aspect, the subject is a child. In one aspect, the child is over 9.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of multiple sclerosis or psoriasis, the method comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any of the pharmaceutical compositions described herein to a subject with multiple sclerosis, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject. In one aspect, the subject experiences one or more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%. In another aspect, the subject is a child. In one aspect, the child is over 9.

Another embodiment described herein is a pharmaceutical composition comprising any of the pharmaceutical compositions described herein for administration to a subject having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis, comprising a therapeutically effective amount of one or more fumarate esters, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject and wherein the administration does not require titration of the pharmaceutical composition. In one aspect, the subject experiences one or

more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%. In another aspect, the subject is a child. In one aspect, the child is over 9.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis, the method comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any of the pharmaceutical compositions described herein to a subject in need thereof, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject and wherein the administration does not require titration of the pharmaceutical composition. In one aspect, the subject experiences one or more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%. In another aspect, the subject is a child. In one aspect, the child is over 9.

Another embodiment described herein is a pharmaceutical composition comprising any of the compositions described herein for administration to a subject having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising a therapeutically effective amount of one or more fumarate esters, wherein the pharmaceutical composition is stable at 25 °C 60% RH for at least 1 year.

Another embodiment described herein is a pharmaceutical composition comprising any of the compositions described herein comprising a therapeutically effective amount of one or more fumarate esters for administration to a subject diagnosed with multiple sclerosis or psoriasis.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the pharmaceutical compositions described herein.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective

amount of a fumarate ester comprising any of the pharmaceutical compositions described herein and a therapeutically amount of a leukotriene receptor antagonist. In one aspect, the leukotriene receptor antagonist comprises montelukast or zafirlukast.

Another embodiment described herein is a pharmaceutical composition comprising a matrix fill comprising any of the compositions described herein in Tables 1, 2, and 5–23.

Another embodiment described herein is a pharmaceutical composition for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising a fumarate ester, wherein the pharmaceutical composition exhibits an in vitro dissolution rate (% dissolution per minute) at pH 6.8, as shown in any of Drawings 2–12 described herein.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the pharmaceutical compositions described herein, wherein the composition exhibits an in vitro dissolution rate (% dissolution per minute) at pH 6.8, as shown in any of Drawings 2–12 described herein.

Another embodiment described herein is a pharmaceutical composition for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising a fumarate ester, wherein the pharmaceutical composition exhibits an in vitro dissolution rate at pH 6.8 comprising about 10% to about 80% dissolution after about 10 minutes to about 480 minutes.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the compositions described herein, wherein the pharmaceutical composition exhibits an in vitro dissolution rate (% dissolution per minute) at pH 6.8, as shown in any of Drawings 2–12 described herein.

Another embodiment described herein is a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the pharmaceutical compositions described herein, wherein the pharmaceutical composition is administered without titration of the pharmaceutical composition and without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.

Another embodiment described herein is a pharmaceutical composition for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, comprising a fumarate ester, wherein the pharmaceutical composition is administered without titration of the pharmaceutical composition and without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.

15

**BRIEF DESCRIPTION OF THE DRAWINGS**

FIGURE 1. Scheme for manufacturing enteric soft capsules comprising a DMF matrix.

FIGURE 2. Dissolution of enteric soft capsules comprising two DMF formulations.

FIGURE 3. DMF enteric soft capsule stability.

5 FIGURE 4. DMF release in enteric soft capsules.

FIGURE 5. Surfactants affect DMF release rate.

FIGURE 6. Polyvinylpyrrolidone concentration affects DMF release rate.

FIGURE 7. DMF enteric soft capsules are amenable to controlled or extended release.

FIGURE 8. DMF particle size affects release rate.

10 FIGURE 9. Two-stage dissolution of application batches.

FIGURE 10. Two-stage dissolution of GMP batch compared to application batches.

FIGURE 11. Effects of Povidone K30 and PEG 600 on DMF release rate.

FIGURE 12. Two-stage dissolution of 120 mg DMF enteric soft capsule.

FIGURE 13. DMF enteric soft capsule stability at  $T_0$  and after 3- and 6-month conditions.

15



**DETAILED DESCRIPTION**

Described herein are pharmaceutical compositions of fumarate esters such as dimethyl fumarate, monomethyl fumarate, other pharmacologically active fumarate esters, or combinations thereof.

5           The pharmaceutical compositions described herein provide matrix fills of fumarate esters, such as dimethyl fumarate, monomethyl fumarate, or combinations thereof, and methods for preparation thereof. Also described herein are compositions and methods for manufacturing controlled, delayed, or extended release fumarate esters, dimethyl fumarate, monomethyl fumarate, or combinations thereof as enteric soft capsules. In one embodiment described herein,  
10           the fumarate ester pharmaceutical composition is placed within an enteric soft capsule shell. In another embodiment, the fumarate ester is in the form of solid microparticles of defined size within a matrix comprising a lipid or lipophilic vehicle.

As used herein, the term “fumarate ester” or “FAE” refers to any pharmacologically active dialkyl fumarate ester, such as dimethyl fumarate, monomethyl fumarate, or other  
15           fumarate esters, acids, salts, or derivatives thereof, and combinations or mixtures of any of the foregoing.

The terms “active ingredient” or “active pharmaceutical ingredient” as used herein refer to a pharmaceutical agent, active ingredient, compound, or substance, compositions, or mixtures thereof, that provide a pharmacological, often beneficial, effect.

20           The terms “dosage” or “dose” as used herein denote any form of the active ingredient formulation that contains an amount sufficient to produce a therapeutic effect with a single administration. The dosage form used herein is for oral administration. The preferred oral dosage forms are soft capsules, or preferably, enteric soft capsules.

25           The terms “active pharmaceutical ingredient load” or “drug load” as used herein refers to the quantity (mass) of the active pharmaceutical ingredient comprised in a single soft capsule fill.

The term “formulation” or “composition” as used herein refers to the drug in combination with pharmaceutically acceptable excipients. This term includes orally administrable formulations as well as formulations administrable by other means.

30           The term “titration” as used herein refers to the incremental increase in drug dosage to a level that provides the optimal therapeutic effect.

The term “controlled release” as used herein refers to a composition that does not immediately releases an active ingredient. “Controlled release” as used herein encompasses the terms “modified release,” “sustained release,” “extended release,” and “delayed release.”

5 The term “delayed release” as used herein refers to a composition that releases an active ingredient according to a desired profile over an extended period under physiological conditions or in an in vitro test. By “extended period” it is meant a continuous period of time of at least about 20 minutes, about 30 minutes, about 1 hour; about 2 hours; about 4 hours; about 6 hours; about 8 hours; about 10 hours; about 12 hours; about 14 hours; about 16 hours; about 18 hours; about 20 hours about 24 hours; or even longer.

10 The term “modified release” as used herein refers to a composition that releases an active ingredient at a slower rate than does an immediate release formulation under physiological conditions or in an in vitro test.

The term “sustained” release” as used herein refers to a composition that releases an active ingredient over an extended period of time, for example minutes, hours, or days, such that  
15 less than all the active ingredient is released initially. A sustained release rate may provide, for example, a release of a certain specified amount of a drug or active ingredient from a dosage form, over a certain period, under physiological conditions or in an in vitro test.

The term “extended release” as used herein refers to a composition that releases an active ingredient over an extended period, such as of at least about 20 minutes, about 30 minutes, about  
20 1 hour; about 2 hours; about 4 hours; about 6 hours; about 8 hours; about 10 hours; about 12 hours; about 14 hours; about 16 hours; about 18 hours; about 20 hours about 24 hours; or even longer; specifically over a period of at least 18 hours under physiological conditions or in an in vitro assay.

The term “ $C_{max}$ ” as used herein refers to the maximum observed blood (plasma, serum, or  
25 whole blood) concentration or the maximum blood concentration calculated or estimated from a concentration to time curve, and is expressed in units of mg/L or ng/mL, as applicable.

The term “ $C_{min}$ ” as used herein refers to the minimum observed blood (plasma, serum, or whole blood) concentration or the minimum blood concentration calculated or estimated from a concentration to time curve, and is expressed in units of mg/L or ng/mL, as applicable.

The term “ $C_{avg}$ ” as used herein refers to the blood (plasma, serum, or whole blood) concentration of the drug within the dosing interval, is calculated as AUC/dosing interval, and is expressed in units of mg/L or ng/mL, as applicable.

5 The term “ $T_{max}$ ” as used herein refers to the time after administration at which  $C_{max}$  occurs, and is expressed in units of hours (h) or minutes (min), as applicable.

The term “ $AUC_{0 \rightarrow \tau}$ ” as used herein refers to area under the blood (plasma, serum, or whole blood) concentration versus time curve from time zero to time tau ( $\tau$ ) over a dosing interval at steady state, where tau is the length of the dosing interval, and is expressed in units of h·mg/L or h·ng/mL, as applicable. For example, the term  $AUC_{0 \rightarrow 12}$  as used herein refers to the  
10 area under the concentration versus time curve from 0 to 12 hours.

The term “ $AUC_{0 \rightarrow \infty}$ ” as used herein refers to the area under the blood (plasma, serum, or whole blood) concentration versus time curve from time 0 hours to infinity, and is expressed in units of h·mg/L or h·ng/mL, as applicable.

15 The term “ $AUC_{overall}$ ” as used herein refers to the combined area under the blood (plasma, serum, or whole blood) concentration versus time curve, and is expressed in units of h·mg/L (or h·ng/mL) for at least one or more doses of the pharmaceutical compositions described herein. In one aspect, the “ $AUC_{overall}$ ” refers to the combined area under the blood concentration versus time curve for at least two doses of the pharmaceutical compositions described herein.

20 The term “treating” refers to administering a therapy in an amount, manner, or mode effective to improve a condition, symptom, or parameter associated with a disorder.

The term “prophylaxis” refers to preventing or reducing the progression of a disorder, either to a statistically significant degree or to a degree detectable to one skilled in the art.

The term “substantially” as used herein means to a great or significant extent, but not completely.

25 The term “about” as used herein refers to any value that is within a variation of up to  $\pm 10\%$  of the value modified by the term “about.”

As used herein, “a” or “an” means one or more unless otherwise specified.

Terms such as “include,” “including,” “contain,” “containing” and the like mean “comprising.”

30 The term “or” can be conjunctive or disjunctive.

One embodiment described herein, is controlled release pharmaceutical composition comprising an enteric soft capsule comprising a matrix comprising fumarate esters.

In another embodiment, the enteric soft capsule provides controlled release properties.

In another embodiment, the matrix fill provides controlled release properties. Such controlled release matrix fills are described in International Patent Application Publication No. WO 2005/009409; U.S. Patent Application Publication No. US 2006/0115527; U.S. Patent Nos. 8,293,270; and 8,333,989, each of which are incorporated by reference herein for such teachings. In one aspect, the matrix is configured to provide controlled release, extended release, sustained release, delayed release, or combinations thereof.

In another embodiment, the matrix comprises a lipid or lipophilic vehicle that provides a suspension of fumarate ester microparticles having defined sizes. In one aspect, an enteric soft capsule comprising a suspension of fumarate ester microparticles provides controlled release delivery of the fumarate ester.

In another embodiment, the pharmaceutical composition comprises matrix fills for fumarate esters, such as dimethyl fumarate, monomethyl fumarate, or derivatives thereof, based on lipids or lipophilic vehicles. The described matrices have a hydrophobic (lipophilic) surface in contact with the hydrophilic soft enteric capsule shell to minimize any potential shell-fill interactions, such as when enteric soft capsules are filled with hydrophilic vehicles.

Described herein are methods for manufacturing matrix fills comprising fumarate esters, such as dimethyl fumarate, monomethyl fumarate, or derivatives thereof, in a controlled release enteric soft capsule in the form of a suspension, where part or all of the fumarate ester is suspended within the matrix. Also provided are compositions and formulations where the fumarate ester is incorporated into a one-phase or two-phase matrix.

Also described herein are methods for manufacturing matrix fills comprising fumarate esters or derivatives thereof, in a delayed release enteric soft capsule in the form of a suspension, where part or all of the fumarate ester is suspended within the matrix.

Described herein are methods for manufacturing matrix fills comprising fumarate esters or derivatives thereof, in an extended release enteric soft capsule in the form of a suspension, where part or all of the fumarate ester is suspended within the matrix.

Another embodiment described herein is a controlled, delayed, or extended release enteric soft capsule having a shell and a matrix fill, wherein the matrix fill includes fumarate

esters such as dimethyl fumarate, monomethyl fumarate, or derivatives thereof, suspended as solid particles in a lipid or lipophilic vehicle. In another embodiment, the lipid or lipophilic vehicle comprises a vegetable oil, hydrogenated vegetable oil, fatty acid, wax, fatty acid ester, or a combination thereof.

5 Exemplary lipid or lipophilic vehicles comprise mineral oil; light mineral oil; natural oils (e.g., vegetable, corn, canola, sunflower, soybean, olive, coconut, cocoa, peanut, almond, cottonseed, persic, sesame, squalane, castor, cod liver) hydrogenated vegetable oil; partially hydrogenated oils; beeswax; polyethoxylated beeswax; paraffin; normal waxes; medium chain medium chain monoglycerides, diglycerides and triglycerides; higher aliphatic alcohols; higher  
10 aliphatic acids; long chain fatty acids; saturated or unsaturated fatty acids; hydrogenated fatty acids; fatty acid glycerides; polyoxyethylated oleic glycerides; monoglycerides and diglycerides; mono-, bi- or tri-substituted glycerides; glycerol mono-oleate esters; glycerol mono-caprate; glyceryl monocaprylate; propylene glycol dicaprylate; propylene glycol monolaurate; glyceryl palmitostearate; glyceryl behenate; diethyleneglycol palmitostearate; polyethyleneglycol  
15 stearate; polyoxyethyleneglycol palmitostearate; glyceryl mono palmitostearate; cetyl palmitate; polyethyleneglycol palmitostearate; dimethylpolysiloxane; mono- or di-glyceryl behenate; fatty alcohols associated with polyethoxylate fatty alcohols; cetyl alcohol; octyl dodecanol; myristyl alcohol; isopropyl myristate, isopropyl palmitate, stearic acid, or stearyl alcohol, inter alia, or combinations thereof.

20 In one embodiment, the matrix comprises a solvent or solubility enhancing agent. Exemplary solvents or solubility enhancing agents useful for the matrix fills described herein include Capmul<sup>®</sup> MCM, Captex<sup>®</sup> 355, Cremophor<sup>®</sup> RH 40, Croscarmellose, Crospovidone, Crospovidone CL, Crospovidone CL-F, Crospovidone CL-M, Imwitor<sup>®</sup> 742, Kollidon<sup>®</sup> CL, Kollidon<sup>®</sup> CL-F, Kollidon<sup>®</sup> CL-M, Labrafac<sup>™</sup> Lipophile WL 1349, Labrafil<sup>®</sup> M2125CS,  
25 Labrasol<sup>®</sup>, Lutrol<sup>®</sup> F 68, Maisine<sup>™</sup> 35-1, mannitol, Miglyol<sup>®</sup> 812, Pearlitol<sup>®</sup> Flash, Peceol<sup>®</sup>, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 3350, Plurol<sup>®</sup> Oleique CC 497, Povidone K 17, Povidone K 30, propylene glycol, or combinations thereof.

In one embodiment, the matrix comprises solid particles of fumarate ester suspended in a lipid or lipophilic vehicle of vegetable oil, hydrogenated vegetable oil, fatty acid, fatty acid ester,  
30 or a combination thereof. The matrix can also comprise solvents and suspension agents such as

polyethylene glycols of molecular weight ranging from about 200 to about 8000, polyvinylpyrrolidone, or combinations thereof.

In another embodiment, the matrix fill comprises a release regulator such as a fatty acid salt, fatty acid ester, or fatty acid polyoxyethylene derivative. The release regulator can also be a surfactant having a hydrophilic/lipophilic balance (HLB) value between about 2 and about 40. The HLB characteristic of surfactants can be determined in accordance with “*Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences*,” Fourth Edition, pp. 371-373, A. Martin, Ed., Lippincott Williams & Wilkins, Philadelphia (1993), which is incorporated by reference herein for such teachings.

In another embodiment, the matrix comprises emulsifying or solubilizing agents such as acacia, cholesterol, diethanolamine, glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, monoethanolamines, oleic acids, oleyl alcohols, poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol diacetate, propylene glycol monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, trolamine, emulsifying wax, or combinations thereof.


In another embodiment, the matrix comprises a neutralizing agent. Without being bound to any theory, the neutralizing agent stabilizes the fumarate ester in the matrix fill by preventing hydrolysis. In addition, without being bound by any theory, the neutralizing agent stabilizes the enteric soft capsule shell by forming salts with the methylacrylate moieties from the capsule shell. In one aspect, the neutralizing agent comprises an organic acid, ester, or salt. In another aspect, the neutralizing agent comprises at least one of lactate, fumarate, caprylate, caprate, oleate, maleate, succinate, tartrate, citrate, glutamate, gluconate, esters or salts thereof, or combinations thereof. In one aspect, the neutralizing agent is lactic acid.

In another embodiment, the matrix includes a hydrophilic internal phase and a lipid or lipophilic external phase. The hydrophilic internal phase comprises polypropylene glycol or polyethylene glycol of molecular weight ranging from about 200 to about 8000. In another embodiment, the internal phase comprises hydroalcoholic solutions of cellulose derivatives, polyacrylates, polyvinyl polymers, or combinations thereof. In one embodiment, the internal phase comprises polymers such as methylcellulose, hydroxypropylmethylcellulose,

polymethylmethacrylate, or polyvinylpyrrolidone (PVP). In one embodiment, the internal phase of the matrix state is “fluid” or “structured.” A “fluid” internal phase, as used herein, means a completely flowable liquid whose globules can aggregate to make a larger globule. A “structured” internal phase, as used herein, means a solid, semisolid, or a gel whose shape is relatively stable and does not usually aggregate to form a large globule. A structured internal phase can provide controlled drug release and stabilize the physical state of the matrix. Without being bound to any theory, the structured nature of the matrix impedes solvation or diffusion of the fumarate ester out of the matrix. In another embodiment, the external phase comprises a vegetable oil, hydrogenated vegetable oil, fatty acid, fatty acid ester, wax, or a combination thereof. In another embodiment, fumarate ester is dispersed in the internal phase as a suspension form.

In another embodiment, the matrix fill is of an emulsion type, where the fumarate ester is distributed in one or both of the external (lipophilic and internal phases. The external phase of the emulsion matrix fill comprises lipid or lipophilic vehicles similar to those described herein. The fumarate ester can be dispersed in the internal phase as a solution or as a suspension. For example, one portion of the fumarate ester in the form of a powder is incorporated in the internal phase, while another portion is dispersed in the external phase as solid particles. An emulsion-type matrix may comprise a surfactant or combination of surfactants having HLB values ranging from about 2 to about 40, including all integers within the specified range. In one aspect, the HLB range comprises from about 8 to about 20, including all integers within the specified range.

In one embodiment, the pharmaceutical composition described herein comprises an enteric soft capsule comprising a matrix comprising a lipid or lipophilic vehicle that provides a suspension of a fumarate ester. In one embodiment described herein, the fumarate ester is a dialkyl fumarate of Formula I:



wherein  $R^1$  and  $R^2$ , which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated  $C_{1-20}$  alkyl radical, which may be optionally substituted with halogen (Cl, F, I, Br), hydroxy,  $C_{1-4}$  alkoxy, nitro, or cyano for preparing a pharmaceutical composition as described herein.

The C<sub>1-20</sub> alkyl radicals, C<sub>1-8</sub> alkyl radicals, and C<sub>4-5</sub> alkyl radicals are, for example, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *sec*-butyl, *t*-butyl, pentyl, cyclopentyl, 2-ethyl hexyl, hexyl, cyclohexyl, heptyl, cycloheptyl, octyl, vinyl, allyl, 2-hydroxyethyl, 2 or 3-hydroxy propyl, 2-methoxy ethyl, methoxy methyl or 2- or 3-methoxy propyl. In one aspect, at least one of R<sup>1</sup> or R<sup>2</sup> is a C<sub>1-5</sub> alkyl, especially methyl or ethyl. In another aspect, R<sup>1</sup> and R<sup>2</sup> are the same or different C<sub>1-5</sub> alkyl radicals such as methyl, ethyl, *n*-propyl, or *t*-butyl. In one aspect, R<sup>1</sup> and R<sup>2</sup> are the same or different C<sub>1-5</sub> alkyl radicals such as methyl and ethyl. In one aspect, R<sup>1</sup> and R<sup>2</sup> are identical and are methyl or ethyl. In one aspect, the fumarate ester is monomethyl fumarate, dimethyl fumarate, methyl ethyl fumarate, or diethyl fumarate. In one aspect, the fumarate ester is monomethyl fumarate, dimethyl fumarate, or a combination thereof. In one aspect, the fumarate ester is monomethyl fumarate. In another aspect, the fumarate ester is dimethyl fumarate.

In one embodiment, the pharmaceutical compositions described herein may comprise pharmaceutically acceptable salts of the active ingredient. The term “pharmaceutically acceptable salts” of an active ingredient includes alkali metal salts such as, sodium or potassium salts, alkaline earth metal salts such as, for example, calcium and magnesium salts, and salts with organic or inorganic acid such as, for example, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, maleic acid, succinic acid, tartaric acid, methanesulphonic acid, toluenesulphonic acid, inter alia. In another embodiment, the active ingredient may also be in the form of pharmaceutically acceptable uncharged or charged molecules, molecular complexes, solvates, or anhydrates thereof, and, if relevant, single isomers, enantiomers, racemic mixtures, or mixtures thereof. In another embodiment, the active pharmaceutical ingredient may be in any of its crystalline, polymorphous, semi-crystalline, amorphous or polyamorphous forms, or mixtures thereof.

The fumarate esters described herein can be prepared by processes known in the art. *See, e.g.,* EP 0 312 697 and U.S. Patent Application Publication Nos. US 2013/0295169; US 2014/0179779; and US 2014/0200363, each of which is incorporated by reference herein for such teachings.

In one embodiment, the pharmaceutical composition comprises an active ingredient or drug. In one embodiment, the active ingredient or drug is a pharmacologically active fumarate ester. In one embodiment described herein, the active ingredient is a dialkyl fumarate. In one



embodiment described herein, the active ingredient is a fumarate ester or combination of fumarate esters. In one embodiment described herein, the active ingredient is dimethyl fumarate. In another embodiment described herein, the active ingredient is monomethyl fumarate. In another embodiment described herein, the active ingredient is a combination of dimethyl fumarate and monomethyl fumarate. In another embodiment described herein, the active ingredient is a combination of dimethyl fumarate, monomethyl fumarate, and other pharmacologically active fumarate esters, acids, salts, or derivatives thereof. In another embodiment, the active ingredient or drug comprises dimethyl fumarate, monomethyl fumarate, other pharmacologically active fumarate esters, acids, or salts, derivatives thereof, or combinations thereof. In another embodiment, the active ingredient comprises dimethyl fumarate, monomethyl fumarate, or derivatives thereof, combined with aspirin, ibuprofen, naproxene, diclofenac, ketoprofen, celecoxib, other non-steroidal anti-inflammatory active drugs (NSAIDs), or combinations thereof. In one embodiment, the pharmaceutical composition comprises a fumarate ester combined with aspirin.

In another embodiment, the pharmaceutical composition comprises a fumarate ester combined with one or more leukotriene receptor antagonists. In another embodiment, the pharmaceutical composition comprises a fumarate ester combined with montelukast (Singular<sup>®</sup>) or zafirlukast (Accolate<sup>®</sup>). In another embodiment, the pharmaceutical composition comprises a fumarate ester combined with montelukast or zafirlukast and an NSAID. In another embodiment, the pharmaceutical composition comprises a fumarate ester combined with montelukast or zafirlukast and aspirin.

In one embodiment, the fumarate ester-to-matrix ratio range comprises from about 1:50 to about 1:1 by weight, including all ratios within the specified range. In another embodiment, the fumarate ester-to-matrix ratio range comprises from about 1:10 to about 1:1 by weight, including all ratios within the specified range. In one aspect, the fumarate ester-to-matrix ratio comprises about 1:9 to about 1:1 by weight, including all ratios within the specified range. In another aspect, the fumarate ester-to-matrix ratio range comprises from about 1:5 to about 1:1 by weight, including all ratios within the specified range. In another aspect, the fumarate ester-to-matrix ratio is about 1:5; about 1:4; about 1:3; about 1:2; about 1:1; or about 0.5:1. In other aspects, the fumarate ester-to-matrix ratio is 1:3.5; 1:3.1; 1:2.9; 1:2.3; or 1:1.5.

In one embodiment, the active ingredient comprises about 1% to about 70% of the matrix, including each integer within the specified range. In another embodiment, the active ingredient comprise about 70%, about 60%, about 50%, about 40% about 30% , about 20%; about 15%; about 10%; about 5%; about 2%, or about 1% of the matrix. In one aspect, the active ingredient comprises about 64% of the matrix. In another embodiment, the active ingredient comprises about 57% of the matrix. In another embodiment, the active ingredient comprises about 50% of the matrix. In another embodiment, the active ingredient comprises about 32% of the matrix. In another embodiment, the active ingredient comprises about 30% of the matrix. In another embodiment, the active ingredient comprises about 25% of the matrix.

In one embodiment, the solid fumarate ester particles are milled or micronized. In one embodiment, the fumarate ester comprises a particle size range of about 1 to about 500  $\mu\text{m}$ , including each integer within the specified range. In one aspect, the micronized solid fumarate ester particles have mean particle distributions of about 1  $\mu\text{m}$ , 2  $\mu\text{m}$ , about 5  $\mu\text{m}$ , about 10  $\mu\text{m}$ , about 15  $\mu\text{m}$ , about 20  $\mu\text{m}$ , about 25  $\mu\text{m}$ , about 30  $\mu\text{m}$ , about 35  $\mu\text{m}$ , about 40  $\mu\text{m}$ , about 45  $\mu\text{m}$ , about 50  $\mu\text{m}$ , about 55  $\mu\text{m}$ , about 60  $\mu\text{m}$ , about 65  $\mu\text{m}$ , about 70  $\mu\text{m}$ , about 75  $\mu\text{m}$ , about 80  $\mu\text{m}$ , about 85  $\mu\text{m}$ , about 90  $\mu\text{m}$ , about 95  $\mu\text{m}$ , about 100  $\mu\text{m}$ , about 105  $\mu\text{m}$ , about 110  $\mu\text{m}$ , about 115  $\mu\text{m}$ , about 120  $\mu\text{m}$ , about 125  $\mu\text{m}$ , about 130  $\mu\text{m}$ , about 135  $\mu\text{m}$ , about 140  $\mu\text{m}$ , about 145  $\mu\text{m}$ , about 150  $\mu\text{m}$ , about 155  $\mu\text{m}$ , about 160  $\mu\text{m}$ , about 165  $\mu\text{m}$ , about 170  $\mu\text{m}$ , about 175  $\mu\text{m}$ , about 180  $\mu\text{m}$ , about 185  $\mu\text{m}$ , about 190  $\mu\text{m}$ , about 195  $\mu\text{m}$ , about 200  $\mu\text{m}$ , about 205  $\mu\text{m}$ , about 210  $\mu\text{m}$ , about 215  $\mu\text{m}$ , about 220  $\mu\text{m}$ , about 225  $\mu\text{m}$ , about 230  $\mu\text{m}$ , about 235  $\mu\text{m}$ , about 240  $\mu\text{m}$ , about 245  $\mu\text{m}$ , about 250  $\mu\text{m}$ , about 255  $\mu\text{m}$ , about 260  $\mu\text{m}$ , about 265  $\mu\text{m}$ , about 270  $\mu\text{m}$ , about 275  $\mu\text{m}$ , about 280  $\mu\text{m}$ , about 285  $\mu\text{m}$ , about 290  $\mu\text{m}$ , about 295  $\mu\text{m}$ , about 300  $\mu\text{m}$ , about 305  $\mu\text{m}$ , about 310  $\mu\text{m}$ , about 315  $\mu\text{m}$ , about 320  $\mu\text{m}$ , about 325  $\mu\text{m}$ , about 330  $\mu\text{m}$ , about 335  $\mu\text{m}$ , about 340  $\mu\text{m}$ , about 345  $\mu\text{m}$ , about 350  $\mu\text{m}$ , about 355  $\mu\text{m}$ , about 360  $\mu\text{m}$ , about 365  $\mu\text{m}$ , about 370  $\mu\text{m}$ , about 375  $\mu\text{m}$ , about 380  $\mu\text{m}$ , about 385  $\mu\text{m}$ , about 390  $\mu\text{m}$ , about 395  $\mu\text{m}$ , about 400  $\mu\text{m}$ , about 405  $\mu\text{m}$ , about 410  $\mu\text{m}$ , about 415  $\mu\text{m}$ , about 420  $\mu\text{m}$ , about 425  $\mu\text{m}$ , about 430  $\mu\text{m}$ , about 435  $\mu\text{m}$ , about 440  $\mu\text{m}$ , about 445  $\mu\text{m}$ , about 450  $\mu\text{m}$ , about 455  $\mu\text{m}$ , about 460  $\mu\text{m}$ , about 465  $\mu\text{m}$ , about 470  $\mu\text{m}$ , about 475  $\mu\text{m}$ , about 480  $\mu\text{m}$ , about 485  $\mu\text{m}$ , about 490  $\mu\text{m}$ , about 495  $\mu\text{m}$ , about 500  $\mu\text{m}$ , or even larger. In another aspect, the solid particles of fumarate ester comprise a distribution of particle sizes, comprising particles of any of the foregoing sizes.

In another embodiment, the solid fumarate ester particles have mean particle size distributions (PSD) of about 20  $\mu\text{m}$  to about 300  $\mu\text{m}$ , including each integer within the specified range. In one aspect, the solid particles of fumarate ester comprise mean particle size distributions of about 20  $\mu\text{m}$ , about 30  $\mu\text{m}$ , 40  $\mu\text{m}$ , about 50  $\mu\text{m}$  60  $\mu\text{m}$ , about 70  $\mu\text{m}$ , about 80  
5  $\mu\text{m}$ , about 90  $\mu\text{m}$ , about 100  $\mu\text{m}$ , about 120  $\mu\text{m}$ , about 140  $\mu\text{m}$ , about 160  $\mu\text{m}$ , about 180  $\mu\text{m}$ , about 190  $\mu\text{m}$ , about 200  $\mu\text{m}$ , about 220  $\mu\text{m}$ , about 240  $\mu\text{m}$ , about 260  $\mu\text{m}$ , about 280  $\mu\text{m}$ , or about 300  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester have a mean particle size distribution of about 260  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester have a mean particle size distribution of about 170  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester  
10 have a mean particle size distribution of about 140  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester have a mean particle size distribution of about 90  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester have a mean particle size distribution of about 80  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester have a mean particle size distribution of about 25  $\mu\text{m}$ . In another aspect, the plurality of mean particle size distributions can comprise particles of about  
15 261  $\mu\text{m}$ , about 168  $\mu\text{m}$ , about 148  $\mu\text{m}$ , about 90  $\mu\text{m}$ , about 80  $\mu\text{m}$ , or about 26  $\mu\text{m}$ . In another aspect, the solid particles of fumarate ester have a mean particle size distribution of less than or equal to about 90  $\mu\text{m}$ . In one aspect, the solid particles of fumarate ester comprise a  $d_{90}$  of less than or equal to about 90  $\mu\text{m}$  ( $d_{90} \leq 90 \mu\text{m}$ ).

In another embodiment, the solid particles of fumarate ester comprise multiple  
20 distributions of particle sizes. In one aspect, the solid particles of fumarate ester may comprise a plurality of mean particle size distributions of from about 20  $\mu\text{m}$  to about 300  $\mu\text{m}$ . In another aspect, the plurality of mean particle size distributions can comprise combinations of about 261  $\mu\text{m}$ , about 168  $\mu\text{m}$ , about 150  $\mu\text{m}$ , about 90  $\mu\text{m}$ , about 80  $\mu\text{m}$ , or about 26  $\mu\text{m}$ . In another aspect, the solid particles of fumarate ester comprise a plurality of mean particle size distributions of  
25 about 30  $\mu\text{m}$  to about 260  $\mu\text{m}$  in a single matrix fill. Any of the foregoing fumarate ester particle size distributions may be combined to provide the desired controlled release profile.

Another embodiment described herein is a method for manufacturing a matrix fill for a controlled release soft enteric capsule comprising particles of fumarate esters such as dimethyl fumarate or monomethyl fumarate of defined sizes. In one aspect, the particles are of a similar  
30 size distribution. In another aspect, the fumarate ester particles comprise varied size distributions. In another aspect, the fumarate ester particles comprise several size distributions.

In another aspect, the fumarate ester particles comprise a mixture of smaller and larger size distributions. Without being bound to any theory, smaller particles are generally solubilized and released more rapidly than larger particles. The release rate can be adjusted to achieve a specific therapeutic window over a defined period and produce controlled release, delayed release, or extended release compositions by combining multiple fumarate ester particle distributions.

Another embodiment described herein is a method for manufacturing a pharmaceutical composition comprising fumarate ester(s) where the fumarate ester does not sublime during processing, manufacturing, after production, or during storage. Soft enteric capsules comprising fumarate ester in the matrix fills described herein are stable for months or years. Without being bound to any theory, it is believed that suspending solid fumarate ester in a lipid or lipophilic vehicle comprising an organic acid prevents or retards sublimation and stabilizes the fumarate ester. In one aspect, the pharmaceutical compositions described herein are stable at 25 °C and 60% relative humidity (RH) for about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 10 months, about 11 months, about 12 months, or even longer. In another aspect, the pharmaceutical compositions described herein are stable for 1 year or longer at 25 °C and 60% RH. In another aspect, the pharmaceutical compositions described herein are stable for 2 years or longer at 25 °C and 60% RH.

Another embodiment described herein is a method for preparing a pharmaceutical matrix comprising a fumarate ester. An exemplary scheme of a manufacturing process is shown in **Figure 1**. The method comprises applying heat to the matrix components during mixing or prior to mixing at about the melting point of the matrix fill composition; and then mixing the fumarate ester with the lipid or lipophilic matrix ingredients using mechanical or ultrasonic forces to form the matrix fill. The matrix fill is flowable such that it can be encapsulated using a rotary die encapsulation machine. In one embodiment, the matrix components are heated to a temperature in the range of from about 25 °C to about 70 °C. The matrix components are heated to a temperature in the range of from about 25 °C to about 30 °C.

In one embodiment, the matrix comprises a lipid or lipophilic vehicle, a neutralizing agent, excipients, and solid particles of fumarate ester. In another aspect, the matrix comprises polyethylene glycols, polyvinylpyrrolidones, oils, and surfactants. In one aspect, the surfactant comprises polysorbate 80 or polyoxyl 40 hydrogenated castor oil. In another aspect, the matrix

comprises dimethyl fumarate, a mixture of mono- and di-glycerides, polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid.

In one embodiment, the matrix comprising fumarate ester comprises the composition shown in **Table 1** including all possible iterations of the specified ranges that provide 100% for the total weight percentage of the composition.

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl Fumarate (PSD 80 $\mu\text{m}$ )	240	32
Capmul <sup>®</sup> MCM	375	50
Povidone K 30	15–52.5	0.01–7
Cremophor <sup>®</sup> RH 40	15–75	2–10
Lactic acid	7.5–37.5	1–5
<b>TOTAL</b>	<b>750 mg</b>	<b>100%</b>

In one embodiment, the matrix comprises about 32% of fumarate ester (PSD: 80  $\mu\text{m}$ ); about 50% of a mixture of mono- and di-glycerides; at least about 0.01–7% polyvinylpyrrolidone; at least about 2–10% polyoxyl 40 hydrogenated castor oil, and at least about 1–5% lactic acid, including all iterations of the specified ranges. In one aspect, the composition prevents sublimation of the FAE during processing and manufacturing. In one aspect, the composition reduces the onset of symptoms of gastrointestinal side effects. In another aspect, the composition is stable for at least 6 months at 25 °C at 60% relative humidity. In another aspect, the composition is stable for at least 24 months.

In one embodiment, the matrix comprises the composition shown in **Table 2** including all possible iterations of the specified ranges that provide 100% for the total weight percentage.

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Monomethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	480	48–60
Capmul <sup>®</sup> MCM	216–470	25–48.0
Cremophor <sup>®</sup> RH 40	7.3–120	0.85–12.0
Povidone K 30	7.3–50	0.85–5.0
Lactic acid	21.7–50	2.55–5.0
<b>TOTAL</b>	<b>850 mg–1000 mg</b>	<b>100%</b>

In another embodiment the matrix fill comprises about 32% of fumarate ester (PSD:  $\leq 90$   $\mu\text{m}$ ); about 25% to about 47% of a mixture of mono- and di-glycerides; at least about 0.01–7% polyvinylpyrrolidone; at least about 0.85–12% polyoxyl 40 hydrogenated castor oil, and at least about 1–5% lactic acid, including all iterations of the specified ranges. In one aspect, the composition prevents sublimation of the FAE during processing and manufacturing. In another aspect, the composition reduces the onset of symptoms of any gastrointestinal side effects. In another aspect, the composition is stable for at least 6 months at 25 °C at 60% relative humidity. In another aspect, the composition is stable for at least 24 months at 25 °C at 60% relative humidity.

In one embodiment, the fumarate ester pharmaceutical composition comprises a soft gelatin capsule shell comprising a matrix comprising a fumarate ester.

In one embodiment, the fumarate ester pharmaceutical composition comprises an enteric soft capsule shell comprising a matrix comprising a fumarate ester. Enteric soft capsules are described in International Patent Application Publication No. WO 2004/030658; U.S. Patent Application Publication No. US 2006/0165778; and U.S. Patent No. 8,685,445, each of which is incorporated by reference herein for such teachings. The enteric soft capsule shell may comprise one or more film forming polymers, one or more enteric acid-insoluble polymers, one or more plasticizers, one or more alkali-neutralizing agents, one or more solvents, optionally one or more colorants, and optionally one or more flavorings or other conventionally accepted pharmaceutical excipients or additives.

Film-former polymers that are useful for creating enteric soft capsules are gelatin or hydroxypropylmethylcellulose (HPMC). In one aspect of the enteric soft capsule shell described herein, the film-forming polymer is gelatin.

Examples of enteric, acid-insoluble polymers are acrylic and methacrylate acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate butyrate, hydroxypropylmethylcellulose phthalate (HPMCP), algenic acid salts such as sodium or potassium alginate, or shellac. Poly(methacrylic acid-co-methyl methacrylate) anionic copolymers based on methacrylic acid and methyl methacrylate are particularly stable and are preferred in some embodiments. Poly(meth)acrylates (methacrylic acid copolymer), available under the trade name EUDRAGIT<sup>®</sup> (Evonik Industries AG, Essen, Germany), are provided as powder or aqueous dispersions. In another aspect, the methacrylic acid copolymer comprises

EUDRAGIT<sup>®</sup> L 30 D-55; EUDRAGIT<sup>®</sup> L 100-55; EUDRAGIT<sup>®</sup> L 100; EUDRAGIT<sup>®</sup> L 12.5; EUDRAGIT<sup>®</sup> S 100; EUDRAGIT<sup>®</sup> S 12.5; EUDRAGIT<sup>®</sup> FS 30 D; EUDRAGIT<sup>®</sup> E 100; EUDRAGIT<sup>®</sup> E 12.5; EUDRAGIT<sup>®</sup> E PO; EUDRAGIT<sup>®</sup> RL 100; EUDRAGIT<sup>®</sup> RL PO; EUDRAGIT<sup>®</sup> RL 30 D; EUDRAGIT<sup>®</sup> RL 12.5; EUDRAGIT<sup>®</sup> RS 100; EUDRAGIT<sup>®</sup> RS PO; EUDRAGIT<sup>®</sup> RS 30 D; EUDRAGIT<sup>®</sup> RS 12.5; EUDRAGIT<sup>®</sup> NE 30 D; EUDRAGIT<sup>®</sup> NE 40 D; EUDRAGIT<sup>®</sup> NM 30 D; other poly(meth)acrylate polymers; or a mixture thereof. In one aspect, the enteric polymer is EUDRAGIT<sup>®</sup> L 100, a methacrylic acid copolymer, Type A. Acid-insoluble polymer specifications are detailed in the United States Pharmacopoeia and in various monographs.

10 In another embodiment described herein, the enteric polymer in the enteric soft capsule shell comprises poly(methacrylic acid-co-ethyl acrylate) 1:1 (e.g., EUDRAGIT<sup>®</sup> L 100-55). In one embodiment described herein, the enteric polymer comprises poly(ethyl acrylate-co-methyl methacrylate) 2:1 (e.g., EUDRAGIT<sup>®</sup> NE 40 D). In another embodiment described herein, the enteric polymer comprises poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 (e.g., EUDRAGIT<sup>®</sup> FS 30 D). In another embodiment described herein, the enteric polymer comprises a combination of poly(methacrylic acid-co-ethyl acrylate) 1:1 and poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1. In another embodiment, the enteric polymer comprises a combination of poly(methacrylic acid-co-ethyl acrylate) 1:1 and poly(ethyl acrylate-co-methyl methacrylate) 2:1. In another embodiment, the enteric polymer comprises a combination of poly(methacrylic acid-co-ethyl acrylate) 1:1, poly(ethyl acrylate-co-methyl methacrylate) 2:1, and poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1.

25 In another embodiment, plasticizers that are useful for creating enteric soft capsules as described herein are glycerol, sorbitol, polyethylene glycol, citric acid, citric acid esters, such as tri-ethyl citrate, or combinations thereof. The weight ratio between the film-forming polymer, the enteric acid-insoluble polymer, and plasticizer is adjusted so that the gel mass is flowable and not too viscous, and can be made into soft capsules using rotary die encapsulation methods.

30 In one embodiment, enteric soft capsule shell compositions are made by dissolving the enteric acid-insoluble polymer in an aqueous solution of an alkali-neutralizing agent such as ammonia, sodium hydroxide, potassium hydroxide, or liquid amines such as tri-ethanol amine or ethylene diamine. The amount of alkali is adjusted to give a final pH value of the gel mass less

than or equal to about pH 9.0. In one embodiment, the final pH does not exceed 8.5. The volatile alkali-neutralizing agent, ammonia is preferred. The film-forming polymer can then be combined with the plasticizer and solvent and then blended with the acid-insoluble gel to make a final homogeneous mix in a heat-controlled vessel with degassing by vacuum. The fugitive ammonia evaporates during degassing. Using the foregoing process, the alkali concentrations do not require heating or neutralizing with acid in order to neutralize the gel mass.

In another embodiment described herein, the enteric soft capsule shell is made using an aqueous dispersion of the acid-insoluble polymer by adding an alkali-neutralizing agent such as ammonium, sodium, or potassium hydroxides, other alkalis, or a combination thereof that will cause the enteric acid-insoluble polymer to dissolve. The plasticizer-wetted, film-forming polymer can then be mixed with the solution of the acid-insoluble polymer. In one embodiment, enteric acid-insoluble polymers in the form of salts of the bases or alkalis as described herein are dissolved directly in water and mixed with the plasticizer-wetted, film-forming polymer.

In one embodiment described herein, enteric acid-insoluble polymers in the form of salts of the bases or alkalis described herein are dissolved directly in water and mixed with the plasticizer-wetted, film-forming polymer. In another embodiment described herein, an aqueous dispersion of the acid-insoluble polymer or polymers is used, which obviates the need for the addition of the alkali-neutralizing agent described herein.

In one embodiment, the enteric soft capsule shell has the composition of **Table 3**, including all possible iterations of the specified ranges that provide 100% for the total weight percentage, including or excluding the optional, excipients, opacifiers, colorants, and flavorings.

<b>Component</b>	<b>Exemplary Component</b>	<b>Composition Range (%)</b>
Film-forming polymer	Gelatin	20–36
Enteric, acid-insoluble polymer	Methacrylic Acid Copolymer	8–20
Plasticizer	Glycerol, Triethyl citrate	15–22
Alkali-neutralizing agents	NH <sub>4</sub> OH (30%), NaOH	1–5
Solvent	Water	20–40
Opacifier	Titanium Dioxide	1–7.5
Colorant (optional)	Various	0.05–1
Flavoring (optional)	Various	0.05–2
Excipients (optional)	Various	1–5



In one embodiment, the enteric soft capsule shell comprises a composition of about 30% film forming polymer; about 10% enteric, acid-insoluble polymer; about 20% plasticizer; about 1% alkali-neutralizing agent; and about 37% solvent.

5 In another embodiment, the weight percentage range of total polymer content (i.e., film forming polymer and enteric acid-insoluble polymer) of the enteric soft capsule described herein is about 30% to about 45%, including all integers within the specified range. In one aspect, the total polymer weight percentage is about 40%. In another aspect, the total polymer weight percentage is about 42%. In another aspect, the total polymer weight percentage is about 45%. In another aspect, the total polymer weight percentage is about 38%.

10 In one embodiment, the weight percentage range of total plasticizer is about 15% to about 22%, including all iterations of integers with the specified range. In one aspect, the total plasticizer weight percentage is about 19%. In another aspect, the total plasticizer weight percentage is about 17.7%. In another aspect, the total plasticizer weight percentage is about 18.9%. In another aspect, the total plasticizer weight percentage is about 19.3%.

15 In one embodiment, the alkali-neutralizing agent is ammonia (ammonium hydroxide; 30% w/v) that is added to comprise a weight percentage of about 1 to about 5% of the total enteric soft capsule composition. In one aspect, 30% w/v ammonia is added to comprise a weight percentage of about 2%. In another aspect, 30% w/v ammonia is added to a weight percentage of about 1.7%. In one aspect, ammonia is added to provide a final pH of about 9 in the enteric soft capsule composition. In another aspect, ammonia is added to provide a final pH of about 8.5 in the enteric soft capsule composition. In another aspect, after the capsules are filled and dried, the ammonia concentration is substantially reduced, owing to the fugitive nature of the volatile alkali-neutralizing agent. In another aspect, practically all of the ammonia is evaporated except for ammonium ions comprising salts with other moieties in the composition.

25 In one embodiment, the weight ratio range of film forming polymer to enteric acid-insoluble polymer (i.e., film forming : enteric) is about 25:75 ( $\approx 0.33$ ) to about 40:60 ( $\approx 0.67$ ) (i.e.,  $\approx 0.33$ – $0.67$ ), including all ratios within the specified range. In one aspect, the ratio of film forming polymer to enteric acid-insoluble polymer is about 30:70 ( $\approx 0.43$ ). In another aspect, the ratio of film forming polymer to enteric acid-insoluble polymer is about 28:72 ( $\approx 0.38$ ).

30 In one embodiment, the weight ratio of total plasticizer to film forming polymer is about 20:40 to 21:30 (i.e.,  $\approx 0.5$ – $0.7$ ), including all ratios within the specified range. In one aspect, the

weight ratio of total plasticizer to film forming polymer is about 20:40 ( $\approx 0.5$ ). In another aspect, the weight ratio of total plasticizer to film forming polymer is about 21:30 ( $\approx 0.7$ ). In another aspect, the weight ratio of total plasticizer to film forming polymer is about 19:29 ( $\approx 0.65$ ). In another aspect, the weight ratio of total plasticizer to film forming polymer is about 19.3:29.2  
5 ( $\approx 0.66$ ).

In one embodiment, the weight ratio of total plasticizer to enteric acid-insoluble polymer is about 1:1 to about 2:1 ( $\approx 1-2$ ), including all ratios within the specified range. In one aspect, the weight ratio of total plasticizer to enteric acid-insoluble polymer is about 11:10 ( $\approx 1.1$ ). In another aspect, the weight ratio of total plasticizer to enteric acid-insoluble polymer is about  
10 14:10 ( $\approx 1.4$ ). In another aspect, the weight ratio of total plasticizer to enteric acid-insoluble polymer is about 17:10 ( $\approx 1.7$ ). In another aspect, the weight ratio of total plasticizer to enteric acid-insoluble polymer is about 20:10 ( $\approx 2$ ). In another aspect, the weight ratio of total plasticizer to enteric acid-insoluble polymer is about 19.3:11.2 ( $\approx 1.73$ ).

In one embodiment, the weight ratio range of total plasticizer to total polymer (film forming and enteric acid-insoluble polymer) is about 18:45 to about 20:40 (i.e.,  $\approx 0.40-0.5$ ), including all ratios within the specified range. In one aspect, the weight ratio range of total plasticizer to total polymer is about 18:45 ( $\approx 0.40$ ). In another aspect, the weight ratio range of total plasticizer to total polymer is about 19:40 ( $\approx 0.475$ ). In another aspect, the weight ratio range of total plasticizer to total polymer is about 20:40 ( $\approx 0.5$ ). In another aspect, the weight  
20 ratio range of total plasticizer to total polymer is about 19.3:40.4 ( $\approx 0.477$ ).

In one embodiment, the solvent comprises about 20% to about 40% of the enteric soft capsule composition, including all integers within the specified range. In one embodiment, the solvent is water. The quantity of water in the composition varies depending on the quantities of the other ingredients. For example, the quantity of opacifier, colorant, flavoring, or other  
25 excipients can change the percentage of water present the composition. In one embodiment, the weight percentage of water is as much as suffices to bring the total weight percentage to 100% (i.e., quantum sufficiat; q.s.). In another embodiment, the water comprises about 20%, about 25%, about 30%, about 35%, or about 40% of the enteric soft capsule composition. In another embodiment, water comprises about 35% to about 40% of the enteric soft capsule composition.  
30 In one embodiment, water comprises about 37% of the composition.

In one embodiment, the final moisture (water) content of the enteric soft capsule is from about 8% to about 15%, including all integers within the specified range. In another embodiment, the moisture content is about 8% to about 12%, including all integers within the specified range. In one aspect, the final moisture content is about 8%. In one aspect, the final moisture content is about 9%. In one aspect, the final moisture content is about 10%. In one aspect, the final moisture content is about 11%. In another aspect, the final moisture content is about 12%.

In one embodiment, the enteric soft capsule shell has the exemplary composition shown in **Table 4**.

10

<b>Table 4. Exemplary Enteric Soft Capsule Shell Composition</b>	
<b>Component</b>	<b>Percent weight</b>
Gelatin	29.2
Methacrylic Acid Copolymer (EUDRAGIT <sup>®</sup> L 100)	11.2
Glycerol	18.0
Triethyl citrate	1.3
Ammonium hydroxide	1.7
Titanium dioxide	1.5
Water	37.1
<b>TOTAL</b>	<b>100%</b>
Final pH	8.5–9.0
Total polymer % weight (gelatin + enteric)	40.4%
Gelatin % wt of total polymer (gelatin + enteric)	72.4%
Enteric % wt of total polymer (gelatin + enteric)	27.6%
Ratio of Enteric to Gelatin	11.2 : 29.2 (0.38)
Total plasticizer % weight (glycerol + triethyl citrate)	19.3%
Ratio of total plasticizer to total polymer	19.3 : 40.4 (0.48)
Ratio total plasticizer to gelatin	19.3 : 29.2 (0.66)
Ratio total plasticizer to enteric	19.3 : 11.2 (1.73)
Water content in dried enteric soft capsule:	8–15%

In one embodiment, the enteric soft capsule shell comprises about 30% gelatin; about 10% poly(methyl) acrylate copolymer; about 18% glycerol; about 1% triethyl citrate; about 1.5% ammonia; about 37% water; and about 1.5% titanium dioxide.

In another embodiment, the enteric soft capsule is described in U.S. Provisional Patent Application No. 62/015,063, which is incorporated by reference herein for such teachings.

One embodiment described herein provides an enteric acid-insoluble polymer dispersed within the film-forming polymer gel mass that provides the total soft gel composition with

enteric acid-insoluble properties, at relatively low concentrations of the enteric acid-insoluble polymer (e.g., from about 8% to about 20% of the total wet gel mass composition) and without the need of excessive amounts of alkali, thus avoiding denaturation or degradation of the film-forming polymer that can weaken the integrity of the enteric soft capsule shell.

5           Films of the enteric soft capsule shell do not dissolve or disintegrate in acids, such as 0.1 *N* hydrochloric acid or simulated gastric fluid (ca. pH 1.2), despite the fact that the majority of the shell ingredients (i.e., greater than 50%) normally dissolve in, or are miscible with, acids. Enteric soft capsules made using the compositions described herein remain intact in hydrochloric acid or simulated gastric fluid for at least two hours. The capsules readily release the contents  
10 upon shifting the pH of the solution to ca. 6.8, such as that of simulated intestinal fluid.

In another embodiment, the final enteric capsule composition provides films of increased strength without substantially compromising film elasticity. Moreover, films made from the enteric soft capsule compositions as described herein are sealed at normal temperature range typically used for making traditional soft gel capsules. In one aspect, enteric soft capsules are  
15 made using a rotary die apparatus as described in U.S. Patent Nos. 5,459,983; 5,146,730; and 6,482,516, each of which are incorporated by reference herein for such teachings.

Another embodiment described herein includes a process of manufacturing enteric soft capsules comprising the pharmaceutical composition as described herein. The process includes preparing a gel mass composition comprising a film-forming, water-soluble polymer and an  
20 enteric acid-insoluble polymer and mixing with appropriate plasticizers and solvent; casting the gel mass into films or ribbons using heat-controlled drums or surfaces; and manufacturing a soft capsule comprising a matrix fill using rotary die technology. The thickness of the films or ribbons that form the enteric capsule shell is from about 0.010 inches ( $\approx 0.254$  mm) to about 0.050 inches ( $\approx 1.27$  mm), including all integers within the specified range. The shell thickness  
25 comprises about 0.010 inch ( $\approx 0.254$  mm), about 0.015 inch ( $\approx 0.381$  mm), about 0.02 in ( $\approx 0.508$  mm), about 0.03 in ( $\approx 0.762$  mm), about 0.04 in ( $\approx 1.02$  mm), or about 0.05 in ( $\approx 1.27$  mm). In one embodiment, the thickness is about 0.02 inches ( $\approx 0.508$  mm) to about 0.040 inches ( $\approx 1.02$  mm). In one embodiment, the shell thickness is about 0.028 inches ( $\approx 0.711$  mm). In another embodiment, the shell thickness is about 0.033 inches ( $\approx 0.838$  mm). In another embodiment, the  
30 shell thickness is about 0.038 inches ( $\approx 0.965$  mm).

In one embodiment described herein, the enteric soft capsule shell described herein, encapsulates a matrix fill as described herein. In another embodiment described herein, the enteric soft capsule shell and encapsulated matrix fill comprises a outer dimension from about 2 oval to about 30 oval including all iterations of capsule size within the specified range (e.g., 2 oval, 3 oval, 4 oval, 5 oval, 6 oval, 7 oval, 8 oval, 10 oval, 12 oval, 16 oval, 20, or 30 oval). In another embodiment described herein, the enteric soft capsule shell and encapsulated matrix fill comprises a outer dimension from about 2 round to about 28 round including all iterations of capsule size within the specified range (e.g., 2 round, 3 round, 4 round, 5 round, 6 round, 7 round, 8 round, 10 round, 12 round, 16 round, 20 round or 28 round). In another embodiment described herein, the enteric soft capsule shell and encapsulated matrix fill comprises a outer dimension from about 2 oblong to about 22 oblong including all iterations of capsule size within the specified range (e.g., 2 oblong, 3 oblong, 4 oblong, 5 oblong, 6 oblong, 7 oblong, 8 oblong, 10 oblong, 11, oblong, 12 oblong, 14 oblong, 16 oblong, 20 oblong, or 22 oblong). Dimension specifications of soft capsules and tablets are known to those skilled in the art. *See Remington's Essentials of Pharmaceutics*, Pharmaceutical Press Publishing Company, London, UK, 1<sup>st</sup> Edition, 2013, which is incorporated by reference herein for such teachings.

The enteric soft capsules described herein can contain a matrix fill that is liquid, semi-solid, or solid. Capsules prepared as described herein can contain a hydrophobic solution or suspension, such as vegetable oils or shortening, or waxes, or combinations thereof. The matrix fill can be formulated to prevent interaction with the capsule shell components and release the pharmaceutical composition at a specified rate.

One embodiment described herein, is a pharmaceutical composition comprising a matrix fill formulation comprising any of the formulations shown in the Tables or Examples described herein. Any of the components of the formulations shown in the Tables or Examples can be increased, decreased, combined, recombined, switched, or removed to provide for a formulation comprising about 100% by weight.

In one embodiment, the pharmaceutical composition described herein provides a dosage of fumarate ester for administration to a subject. The dosage form can be administered, for example, to a subject, or a subject in need thereof. In one aspect, the subject is a mammal, or a mammal in need thereof. In one aspect, the subject is a human, or human in need thereof. In one aspect, the human or human in need thereof is a medical patient. In one aspect, the human

subject is a child (~0–9 years old) or an adolescent (~10–17 years old). In one aspect, the subject is from 0 to 9 years of age. In another aspect, the human subject is from 10 to 17 years of age. In another aspect, the human subject is over 17 years of age. In another aspect, the human subject is an adult ( $\geq 18$  years of age).

5           The dosage form can be administered, for example, 1 $\times$ , 2 $\times$ , 3 $\times$ , 4 $\times$ , 5 $\times$ , 6 $\times$ , or even more times per day. One or more dosage form can be administered, for example, for 1, 2, 3, 4, 5, 6, 7 days, or even longer. One or more dosage forms can be administered, for example, for 1, 2, 3, 4 weeks, or even longer. One or more dosage forms can be administered, for example, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, 1 year, 2, years, 3 years, 4 years, 5 years, over 5 years, a  
10 decade, multiple decades, or even longer. One or more dosage forms can be administered at a regular interval until the subject or subject in need thereof, does not require treatment, prophylaxis, or amelioration of any disease or condition including but not limited to, general autoimmune or neurodegenerative disorders.

In one embodiment, the pharmaceutical composition described herein is administered in  
15 multiple dosages simultaneously. For example, two or more identical dosages are administered at one time. In another embodiment, two or more different dosages are administered at one time. Such dual or different simultaneous doses can be used to provide an effective amount of the pharmaceutical composition to a subject in need thereof.

In another embodiment, the pharmaceutical composition described herein may be used to  
20 treat, prevent, retard the progression of, delay the onset, ameliorate, reduce the symptoms of, or prophylaxis of general autoimmune or neurodegenerative disorders. Neurodegenerative disorders, as used herein, include multiple sclerosis (MS), which includes relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), progressive relapsing multiple sclerosis (PPvMS),  
25 amyotrophic lateral sclerosis (ALS), psoriasis, psoriatic arthritis, Alzheimer's disease, Parkinson's disease, or any combination thereof.

In one embodiment described herein, other conditions, disorders, or diseases are controlled by administration of fumarate esters. The administration of pharmaceutical compositions comprising fumarate esters, as described herein, may be used for treating,  
30 preventing, retarding the progression of, delaying the onset, ameliorating, reducing the symptoms of, or prophylaxis of general autoimmune or neurodegenerative disorders, including

but not limited to, acute dermatitis, adrenal leukodystrophy, AGE-induced genome damage, Alexander's disease, alopecia areata (totalis and universalis), Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, arthritis, asthma, autoimmune diseases, balo concentric sclerosis, Behçet's syndrome, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular insufficiency, central nervous system vasculitis, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic active (lupoid) hepatitis, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease and cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, diabetic retinopathy, fibromyalgia, graft versus host disease, granuloma annulare, granulomas including annulare, Grave's disease, Hashimoto's thyroiditis, hepatitis C viral infection, herpes simplex viral infection, human immunodeficiency viral infection, Huntington's disease, inflammatory bowel disease, irritable bowel disorder, ischemia, juvenile-onset diabetes mellitus, Krabbe disease, lichen planus, macular degeneration, mitochondrial encephalomyopathy, monomelic amyotrophy, multiple sclerosis (MS), myocardial infarction, necrobiosis lipoidica, neurodegeneration with brain iron accumulation, neurodermatitis, neuromyelitis optica, neuropathic pain, neurosarcoidosis, NF- $\kappa$ B mediated diseases, optic neuritis, organ transplantation rejection, paraneoplastic syndromes, Parkinson's disease, Pelizaeus-Merzbacher disease, pemphigus, pernicious anemia, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, radicular pain, radiculopathic pain, reperfusion injury, retinopathic pigmentosa, rheumatoid arthritis (RA), sarcoidosis, sarcoidosis, Schilder's disease, sciatic pain, sciatica, Sjögren's syndrome, subacute necrotizing myelopathy, such as polyarthritis, Susac's syndrome, systemic lupus erythematosus (SLE), tumors, transverse myelitis, ulcerative colitis, or Zellweger syndrome.

One embodiment described herein comprises a method for orally administering a dosage form that provides a total amount of about 20 mg to about 1000 mg (e.g., ~20–1000 mg) of fumarate ester, including each integer within the specified mass range.

In one embodiment, the fumarate ester (FAE) dosage form can comprise, but is not limited to, a total amount of FAE of about 60 mg FAE, about 80 mg FAE, about 100 mg FAE, about 120 mg FAE, about 140 mg FAE, about 160 mg FAE, about 180 mg FAE, about 200 mg FAE, about 220 mg FAE, about 240 mg FAE, about 260 mg FAE, about 280 mg FAE, about 300 mg FAE, about 320 mg FAE, about 340 mg FAE, about 360 mg FAE, about 380 mg FAE, about

400 mg FAE, about 420 mg FAE, about 430 mg FAE, about 440 mg FAE, about 450 mg FAE, about 460 mg FAE, about 470 mg FAE, about 480 mg FAE, about 490 mg FAE, about 500 mg FAE, about 510 mg FAE, about 520 mg FAE, about 530 mg FAE, about 540 mg FAE, about 550 mg FAE, about 560 mg FAE, about 570 mg FAE, about 580 mg FAE, about 590 mg FAE, about  
5 600 mg FAE, or even more.

In one embodiment, the daily dosage is about 100 mg to about 720 mg FAE including each integer within the specified range. In one aspect, the daily dosage is about 120–720 mg FAE, including each integer within the specified range. In one aspect, the daily dosage is about 120 mg FAE. In one aspect, the daily dosage is about 240 mg FAE. In another embodiment, the  
10 daily dosage is about 480 mg FAE. In another embodiment, the daily dosage is about 600 mg FAE. In another embodiment, the dosage is about 720 mg FAE.

In another embodiment, the daily dosage form can comprise, but is not limited to, a total amount of FAE of about 120 mg, about 140 mg, about 180 mg, about 200 mg, about 220 mg, about 240 mg, about 260 mg, about 280 mg, about 300 mg, about 320 mg, about 340 mg, about  
15 360 mg, about 380 mg, about 400 mg FAE, about 420 mg FAE, about 440 mg FAE, about 460 mg FAE, about 480 mg FAE, about 500 mg FAE, about 520 mg FAE, about 540 mg FAE, about 560 mg FAE, about 580 mg FAE, about 600 mg FAE, about 620 mg FAE, about 640 mg FAE, about 660 mg FAE, about 680 mg FAE, about 700 mg FAE, about 720 mg FAE, about 740 mg FAE, about 760 mg FAE, about 780 mg FAE, about 800 mg FAE, about 820 mg FAE, or about  
20 840 mg FAE.

The daily dosage form can contain a total amount of fumarate ester effective for treatment of retarding the progression of, prophylaxis of delaying the onset of, amelioration of, or reducing symptoms of multiple sclerosis or psoriasis or other neurodegenerative disorders.

In one embodiment, the effective amount of fumarate ester can comprise about 20 mg to  
25 about 1000 mg (e.g., 20–1000 mg) of fumarate ester, including each integer within the specified range. In one embodiment, the effective amount can comprise, but is not limited to, about 120–840 mg FAE. The effective amount can comprise, but is not limited to, a total amount of about 120 mg to about 840 mg FAE, about 120 mg to about 820 mg FAE, about 120 mg to about 720 mg FAE, about 120 mg to about 700 mg FAE, about 120 mg to about 680 mg FAE, about 120  
30 mg to about 660 mg FAE, about 120 mg to about 640 mg FAE, about 120 mg to about 600 mg FAE, about 120 mg to about 580 mg FAE, about 120 mg to about 540 mg FAE, about 120 mg to



about 520 mg FAE, about 120 mg to about 500 mg FAE, about 120 mg to about 480 mg FAE, about 120 mg to about 460 mg FAE, about 120 mg to about 440 mg FAE, about 120 mg to about 420 mg FAE, about 120 mg to about 400 mg FAE, about 120 mg to about 380 mg FAE, about 120 mg to about 360 mg FAE, about 120 mg to about 340 mg FAE, about 120 mg to about 320 mg FAE, about 120 mg to about 300 mg FAE, about 120 mg to about 280 mg FAE, about 120 mg to about 260 mg FAE, about 120 mg to about 240 mg FAE, about 120 mg to about 220 mg FAE, about 120 mg to about 200 mg FAE, about 120 mg to about 180 mg FAE, about 120 mg to about 160 mg FAE, or about 120 mg to about 140 mg FAE.

In another embodiment, the effective amount of fumarate ester can comprise, but is not limited to, about 60 mg FAE to about 840 mg FAE (e.g., 60–840 mg FAE), including each integer within the specified range. In one aspect, the effective amount can comprise, but is not limited to, an effective amount of about 60 mg to about 120 mg FAE, about 60 mg to about 140 mg FAE, about 60 mg to about 160 mg FAE, about 60 mg to about 180 mg FAE, about 60 mg to about 200 mg FAE, about 60 mg to about 220 mg FAE, about 60 mg to about 240 mg FAE; about 120 mg to about 140 mg FAE, about 120 mg to about 160 mg FAE, about 120 mg to about 180 mg FAE, about 120 mg to about 200 mg FAE, about 120 mg to about 220 mg FAE, about 120 mg to about 240 mg FAE; about 240 mg to about 260 mg FAE, about 240 mg to about 280 mg FAE, about 240 mg to about 300 mg FAE, about 240 mg to about 320 mg FAE, about 240 mg to about 340 mg FAE, about 240 mg to about 360 mg FAE, about 240 mg to about 380 mg FAE, about 240 mg to about 400 mg FAE, about 240 mg to about 420 mg FAE, about 240 mg to about 440 mg FAE, about 240 mg to about 460 mg FAE, about 240 mg to about 480 mg FAE; about 480 mg to about 500 mg FAE, about 480 mg to about 520 mg FAE, about 48 mg to about 540 mg FAE, about 480 mg to about 560 mg FAE, about 480 mg to about 580 mg FAE, about 480 mg to about 600 mg FAE, about 480 mg to about 620 mg FAE, about 480 mg to about 640 mg FAE, about 480 mg to about 660 mg FAE, about 480 mg to about 680 mg FAE, about 480 mg to about 700 mg FAE, about 480 mg to about 720 mg FAE, about 480 mg to about 740 mg FAE, about 480 mg to about 760 mg FAE, about 480 mg to about 780 mg FAE, about 480 mg to about 800 mg FAE, about 480 mg to about 820 mg FAE, or about 480 mg to about 840 mg FAE.

In one embodiment described herein, the FAE may comprise a suspension having an active pharmaceutical ingredient load (e.g., drug load) of about 1% to about 60%, including each integer within the specified range. In one embodiment, the drug load can comprise about 1%,

about 2%, about 2.5%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 40%, about 50%, about 60%, or even higher. In one aspect, the drug load is about 20%. In one aspect, the drug load is about 30%. In one aspect, the drug load is about 40%. In one aspect, the drug load is about 50%. In one aspect, the drug load is about 60%. In one aspect, the drug load is about 28%. In one aspect, the drug load is about 32%. In one aspect, the drug load is about 44%. In one embodiment, the drug load is about 48%. In one embodiment, the drug load is about 56%.

One embodiment described herein is a pharmaceutical composition comprising any one of the pharmaceutical compositions described herein for administration to a subject having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis, comprising a therapeutically effective amount of one or more fumarate esters, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject; and wherein the administration does not require titration of the pharmaceutical composition.

Another embodiment described herein is a method for treating, retarding the progression of, prophylaxis of, delaying the onset of, ameliorating, or reducing the symptoms of multiple sclerosis or psoriasis comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any one of the pharmaceutical compositions described herein to a subject with multiple sclerosis, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject. In one aspect, after administration of any one the pharmaceutical compositions described herein, the subject experiences one or more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%. In another aspect, the endpoint may be less than about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 45%, about 50%, or greater than about 50%.

Another embodiment described herein is a pharmaceutical composition and a method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, the method comprising the administration of a

therapeutically effective amount of one or more fumarate esters comprising any one of the pharmaceutical compositions described herein to a subject in need thereof, wherein the subject achieves a reduction of annualized relapse rate relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea. In another aspect, the endpoint may be less than about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 45%, about 50%, or greater than about 50%, relative to baseline.

Endpoints for treating multiple sclerosis using fumarate esters are described in the TECFIDERA<sup>®</sup> Prescribing Information (Biogen Idec Inc.), and U.S. Patent Application Publication No. US 2014/0163100, each of which is incorporated by reference herein for such teachings. Other pharmaceutical compositions and methods for treating multiple sclerosis are described in U.S. Patent Nos. 6,509,376; 7,320,999; 7,619,001; 7,803,840; 8,399,514; 8,524,773; and 8,759,393, and International Patent Application Publication No. WO 2013/119677, each of which is incorporated by reference herein for such teachings.

Another embodiment described herein is a pharmaceutical composition for administration to a subject with multiple sclerosis or psoriasis comprising a therapeutically effective amount of one or more fumarate esters, wherein the subject achieves a reduction of annualized relapse rate relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea. In one aspect the reduction may be about 1%, about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 45%, about 50%, or greater than about 50%.

For the treatment of multiple sclerosis (e.g., relapsing forms of MS such as RRMS), the dosage form administered to the subject or subject in need thereof comprises an enteric soft capsule comprising micronized solid particles of a fumarate ester as the only active ingredient or in combination with one or more NSAIDS (e.g., aspirin) or leukotriene receptor antagonists (e.g., montelukast or zafirlukast). In one aspect, the effective amount of fumarate ester (FAE) is about 480 mg per day and the subjects can receive the effective amount, i.e., 240 mg FAE bis in die (BID), in the form of two capsules a day, to be taken orally. In another aspect, the effective amount of FAE is about 480 mg FAE per day and the subjects can receive the effective amount, i.e., 480 mg FAE quaque die (QD), in the form of one capsule a day, to be taken orally. In another aspect, the effective amount of FAE is about 600 mg FAE per day and the subjects can

receive the effective amount, i.e., 600 mg FAE quaque die (QD), in the form of one or more capsules a day, to be taken orally. In another aspect, the effective amount of FAE is about 720 mg FAE per day and the subjects can receive the effective amount, i.e., 720 mg FAE quaque die (QD), in the form of one or more capsules a day, to be taken orally.

5 For the treatment of psoriasis, the dosage form administered to the subject or subject in need thereof comprises an enteric soft capsule comprising micronized solid particles of a fumarate ester as the only active ingredient or in combination with one or more NSAIDS (e.g., aspirin) or leukotriene receptor antagonists (e.g., montelukast or zafirlukast). In one aspect, the effective amount of fumarate ester (FAE) is about 480 mg per day and the subjects can receive  
10 the effective amount, i.e., 240 mg FAE bis in die (BID), in the form of two capsules a day, to be taken orally. In another aspect, the effective amount of FAE is about 480 mg FAE per day and the subjects can receive the effective amount, i.e., 480 mg FAE quaque die (QD), in the form of one capsule a day, to be taken orally. In another aspect, the effective amount of FAE is about  
15 600 mg FAE per day and the subjects can receive the effective amount, i.e., 600 mg FAE quaque die (QD), in the form of one or more capsules a day, to be taken orally. In another aspect, the effective amount of FAE is about 720 mg FAE per day and the subjects can receive the effective amount, i.e., 720 mg FAE quaque die (QD), in the form of one or more capsules a day, to be taken orally.

FAE can cause flushing and gastrointestinal (GI) side effects in some subjects. While the  
20 side effects generally subside soon after subjects start on the treatment, in one aspect the starting dose is 120 mg FAE BID orally for the first 7 days. The dose is increased to the effective dose of 240 mg FAE BID (i.e., about 480 mg FAE per day). In another aspect, the starting dose is 240 mg FAE BID orally for the first 7 days. The dose is increased to the effective dose of 480 mg FAE QD (i.e., about 480 mg FAE per day). For those subjects who experience GI or  
25 flushing side effects, taking FAE with food can improve tolerability. In one aspect described herein, FAE is administered after a meal. In another aspect described herein, FAE is administered after a high-fat meal to reduce or ameliorate the one or more symptoms of flushing, abdominal pain, diarrhea, and nausea in the subject.

In one embodiment, the pharmaceutical compositions described herein can be  
30 administered without titration of the pharmaceutical composition. In one aspect, the

pharmaceutical compositions can be administered without titration and without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.

In one embodiment, the pharmaceutical composition described herein does not elicit the flushing and gastrointestinal side effects when the dose is about 240 mg FAE quaque die (QD) (i.e., 240 mg FAE per day). In one embodiment, the pharmaceutical composition described herein does not elicit the flushing and gastrointestinal side effects when the dose is about 480 mg FAE quaque die (QD) (i.e., 480 mg FAE per day). In one embodiment, the pharmaceutical composition described herein does not elicit the flushing and gastrointestinal side effects when the dose is about 600 mg FAE quaque die (QD) (i.e., 600 mg FAE per day). In one embodiment, the pharmaceutical composition described herein does not elicit the flushing and gastrointestinal side effects when the dose is about 720 mg FAE quaque die (QD) (i.e., 720 mg FAE per day).

In one embodiment, the pharmaceutical composition described herein does not elicit the flushing and gastrointestinal side effects when the effective amount is about 480 mg FAE quaque die (QD) (i.e., 480 mg FAE per day). In another embodiment, the pharmaceutical composition described herein does not elicit flushing and gastrointestinal side effects when the effective amount is about 600 mg FAE quaque die (QD) (i.e., 600 mg FAE per day). In another embodiment, the pharmaceutical composition described herein does not elicit flushing and gastrointestinal side effects when the effective amount is about 720 mg FAE quaque die (QD) (i.e., 720 mg FAE per day).

In another aspect, the administration of about 325 mg of non-enteric coated aspirin 30-minutes prior to FAE dosing can reduce the occurrence and severity of flushing. In one aspect, subjects who experience flushing with gastrointestinal side effects may reduce the dose to 120 mg FAE BID temporarily. Within a month, the effective dose of 240 mg FAE BID should be resumed. In another aspect, subjects who experience flushing with gastrointestinal side effects may reduce the dose to 240 mg FAE BID temporarily. Within a month, the effective dose of 480 mg FAE QD should be resumed.

In one embodiment, a subject administered a FAE pharmaceutical composition described herein may take one or more non-steroidal anti-inflammatory drugs (NSAID) before (for example, about 10 minutes to an hour, e.g., about 30 minutes before) taking a FAE pharmaceutical composition described herein. In one embodiment, the subject administered a dosage form takes the one or more non-steroidal anti-inflammatory drugs to reduce flushing. In

one embodiment, the one or more non-steroidal anti-inflammatory drugs comprise aspirin, ibuprofen, naproxen, ketoprofen, celecoxib, or combinations thereof. The one or more non-steroidal anti-inflammatory drugs can be administered in an amount of about 50 mg to about 500 mg before taking the dosage form described herein. In one embodiment, a subject takes 325 mg aspirin about 30-minutes before taking the dosage forms described herein.

In another embodiment, a subject administered a FAE pharmaceutical composition described herein may take one or more leukotriene receptor antagonists. In another embodiment, a subject administered a FAE pharmaceutical composition described herein may take 10 to 20 mg of montelukast (Singulair<sup>®</sup>) or zafirlukast (Accolate<sup>®</sup>).

In another embodiment described herein, subjects are orally administered one or more non-steroidal anti-inflammatory drugs before taking the dosage form described herein exhibit the same pharmacokinetic properties (e.g.,  $C_{max}$  and AUC) as subjects orally administered the dosage form described herein without administering one or more non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen, naproxen, ketoprofen, celecoxib, or combinations thereof). The NSAID can be administered about 30-minutes before taking the dosage form described herein.

In one embodiment, subjects with multiple sclerosis or psoriasis are administered an enteric soft capsule containing 240 mg FAE, twice-daily for a total daily dose of 480 mg, wherein the enteric soft capsule comprises solid microparticles of FAE in a matrix. In one embodiment, the matrix is a controlled release matrix. In another embodiment, the matrix is a delayed release matrix. In another embodiment, the matrix is an extended release matrix.

In one embodiment, subjects having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, are administered an enteric soft capsule containing about 480 mg FAE, one daily for a total daily dose of about 480 mg, wherein the enteric soft capsule comprises solid microparticles of FAE in a matrix. In one embodiment, the matrix is a controlled release matrix. In another embodiment, the matrix is a delayed release matrix. In another embodiment, the matrix is an extended release matrix.

Pharmacokinetics of fumarate esters, particularly DMF, are described by Sheikh et al., *Clinical Therapeutics* 35(10): 1582-1594 (2013), which is incorporated by reference herein for such teachings.

In one embodiment described herein, a subject is administered a capsule containing 240 mg FAE, twice daily for a total daily dose of 480 mg. In one aspect, the pharmaceutical

composition comprises an immediate release, delayed release, controlled release, or extended release formulation of a fumarate ester. In another aspect, the pharmaceutical composition comprises an enteric soft capsule. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 0.4 mg/L to about 2.41 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 3.4 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 2.41 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 0.4 mg/L to about 0.75 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 0.76 mg/L to about 1.03 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.04 mg/L to about 1.75 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.75 mg/L to about 2.41 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  of at

least 0.4 mg/L, at least 0.5 mg/L, at least 0.6 mg/L, at least 0.7 mg/L, at least 0.8 mg/L, at least 0.9 mg/L, at least 1 mg/L, at least 1.1 mg/L, at least 1.2 mg/L, at least 1.3 mg/L, at least 1.4 mg/L, at least 1.5 mg/L, at least 1.6 mg/L, at least 1.7 mg/L, at least 1.8 mg/L, at least 1.9 mg/L, at least 2 mg/L, at least 2.1 mg/L, at least 2.2 mg/L, at least 2.3 mg/L, at least 2.4 mg/L, at least 2.5 mg/L, at least 2.6 mg/L, at least 2.7 mg/L, at least 2.8 mg/L, at least 2.9 mg/L, at least 3 mg/L, at least 3.1 mg/L, at least 3.2 mg/L, at least 3.3 mg/L, or at least 3.4 mg/L.

In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 2.01 h·mg/L to about 15.2 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 2.01 h·mg/L to about 5.2 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 11.3 h·mg/L to about 15.2 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 5.2 h·mg/L to about 11.2 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  at least about 2.0 h·mg/L, at least about 2.3 h·mg/L, at least about 2.6 h·mg/L, at least about 2.9 h·mg/L, at least 3.2 h·mg/L, at least 3.5 h·mg/L, at least 3.8 h·mg/L, at least 4.1 h·mg/L, at least 4.4 h·mg/L, at least 4.7 h·mg/L, at least 5.0 h·mg/L, at least 5.3 h·mg/L, at least 5.6 h·mg/L, at least 5.9 h·mg/L, at least 6.2 h·mg/L, at least 6.5 h·mg/L, at least 6.8 h·mg/L, at least 7.1 h·mg/L, at least 7.4 h·mg/L, at least 7.7 h·mg/L, at least 8.0 h·mg/L, at least 8.3 h·mg/L, at least 8.6 h·mg/L, at least 8.9 h·mg/L, at least 9.2 h·mg/L, at least 9.5 h·mg/L, at least 9.8 h·mg/L, at least 10.1 h·mg/L, at least 10.4 h·mg/L, at least 10.7 h·mg/L, at least 11.0



h·mg/L, at least 11.3 h·mg/L, at least 11.6 h·mg/L, at least 11.9 h·mg/L, at least 12.2 h·mg/L, at least 12.5 h·mg/L, at least 12.8 h·mg/L, at least 13.1 h·mg/L, at least 13.3 h·mg/L, at least 13.6 h·mg/L, at least 13.9 h·mg/L, at least 14.2 h·mg/L, at least 14.5 h·mg/L, at least 14.8 h·mg/L, or at least 15.2 h·mg/L.

5 In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0\rightarrow 12h}$  ranging from about 1.5 h·mg/L to about 5.6 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0\rightarrow 12h}$  ranging from about 1.5 h·mg/L to about 2.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0\rightarrow 12h}$  ranging from about 2.6 h·mg/L to about 5.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0\rightarrow 12h}$  of at least 2 h·mg/L, of at least 2.1 h·mg/L, at least 2.2 h·mg/L, at least 2.3 h·mg/L, at least 2.4 h·mg/L, at least 2.5 h·mg/L, at least 2.6 h·mg/L, at least 2.7 h·mg/L, at least 2.8 h·mg/L, at least 2.9 h·mg/L, at least 3 h·mg/L, at least 3.1 h·mg/L, at least 3.2 h·mg/L, at least 3.3 h·mg/L, at least 3.4 h·mg/L, at least 3.5 h·mg/L, at least 3.6 h·mg/L, at least 3.7 h·mg/L, at least 3.8 h·mg/L, at least 3.9 h·mg/L, at least 4 h·mg/L, at least 4.1 h·mg/L, at least 4.2 h·mg/L, at least 4.3 h·mg/L, at least 4.4 h·mg/L, at least 4.5 h·mg/L, at least 4.6 h·mg/L, at least 4.7 h·mg/L, at least 4.8 h·mg/L, at least 4.9 h·mg/L, at least 5 h·mg/L, at least 5.1 h·mg/L, at least 5.2 h·mg/L, at least 5.3 h·mg/L, at least 5.4 h·mg/L, or at least 5.5 h·mg/L.

In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0\rightarrow \infty}$  ranging from about 1.5 h·mg/L to about 5.6 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a

fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 1.5 h·mg/L to about 2.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 2.6 h·mg/L to about 5.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  of at least 2 h·mg/L, of at least 2.1 h·mg/L, at least 2.2 h·mg/L, at least 2.3 h·mg/L, at least 2.4 h·mg/L, at least 2.5 h·mg/L, at least 2.6 h·mg/L, at least 2.7 h·mg/L, at least 2.8 h·mg/L, at least 2.9 h·mg/L, at least 3 h·mg/L, at least 3.1 h·mg/L, at least 3.2 h·mg/L, at least 3.3 h·mg/L, at least 3.4 h·mg/L, at least 3.5 h·mg/L, at least 3.6 h·mg/L, at least 3.7 h·mg/L, at least 3.8 h·mg/L, at least 3.9 h·mg/L, at least 4 h·mg/L, at least 4.1 h·mg/L, at least 4.2 h·mg/L, at least 4.3 h·mg/L, at least 4.4 h·mg/L, at least 4.5 h·mg/L, at least 4.6 h·mg/L, at least 4.7 h·mg/L, at least 4.8 h·mg/L, at least 4.9 h·mg/L, at least 5 h·mg/L, at least 5.1 h·mg/L, at least 5.2 h·mg/L, at least 5.3 h·mg/L, at least 5.4 h·mg/L, or at least 5.5 h·mg/L.

In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $T_{max}$  ranging from about 1.5 hours to about 8.5 hours including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $T_{max}$  ranging from about 1.6 hours to about 2.5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $T_{max}$  ranging from about 2.6 hours to about 5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $T_{max}$  ranging from about 5.1 hours to about 7.5 hours, including all iterations of integers within

the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 7.6 hours to about 8.5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit a mean plasma monomethyl fumarate  $T_{\max}$  of at least 1.6 hours, at least 1.8 hours, at least 2 hours, at least 2.2 hours, at least 2.4 hours, at least 2.6 hours, at least 2.8 hours, at least 3 hours, at least 3.2 hours, at least 3.4 hours, at least 3.6 hours, at least 3.8 hours, at least 4 hours, at least 4.2 hours, at least 4.4 hours, at least 4.6 hours, at least 4.8 hours, at least 5 hours, at least 5.2 hours, at least 5.4 hours, at least 5.6 hours, at least 5.8 hours, at least 6 hours, at least 6.2 hours, at least 6.4 hours, at least 6.6 hours, at least 6.8 hours, at least 7 hours, at least 7.2 hours, at least 7.4 hours, at least 7.6 hours, at least 7.8 hours, at least 8 hours, at least 8.2 hours, or at least 8.4 hours.

In one embodiment described herein, a subject is administered a capsule containing 480 mg FAE, once daily for a total daily dose of 480 mg. In one aspect, the pharmaceutical composition comprises an immediate release, delayed release, controlled release, or extended release formulation of a fumarate ester. In another aspect, the pharmaceutical composition comprises an enteric soft capsule. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 0.4 mg/L to about 5.2 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 5.2 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 0.4 mg/L to about 0.75 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$

ranging from about 0.76 mg/L to about 1.03 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.04 mg/L to about 1.75 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.75 mg/L to about 2.41 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 2.42 mg/L to about 3.5 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 3.6 mg/L to about 5.2 mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $C_{\max}$  of at least 1.6 mg/L, at least 1.7 mg/L, at least 1.8 mg/L, at least 1.9 mg/L, at least 2.0 mg/L, at least 2.1 mg/L, at least 2.2 mg/L, at least 2.3 mg/L, at least 2.4 mg/L, at least 2.5 mg/L, at least 2.6 mg/L, at least 2.7 mg/L, at least 2.8 mg/L, at least 2.9 mg/L, at least 3.0 mg/L, at least 3.1 mg/L, at least 3.2 mg/L, at least 3.3 mg/L, at least 3.4 mg/L, at least 3.5 mg/L, at least 3.6 mg/L, at least 3.7 mg/L, at least 3.8 mg/L, at least 3.9 mg/L, at least 4.0 mg/L, at least 4.1 mg/L, at least 4.2 mg/L, at least 4.3 mg/L, at least 4.4 mg/L, at least 4.5 mg/L, at least 4.6 mg/L, at least 4.7 mg/L, at least 4.8 mg/L, at least 4.9 mg/L, at least 5.0 mg/L, or at least 5.1 mg/L

In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 1.5 h·mg/L to about 15.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a

fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 1.5 h·mg/L to about 2.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester,

5 wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.6 h·mg/L to about 5.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$

10 ranging from about 5.6 h·mg/L to about 7.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 7.6 h·mg/L to about 10.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 10.5 h·mg/L to about 15.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a

15 fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  of at least 2.0 h·mg/L, at least 2.3 h·mg/L, at least 2.6 h·mg/L, at least 2.9 h·mg/L, at least 3.2 h·mg/L, at least 3.5 h·mg/L, at least 3.8 h·mg/L, at least 4.1 h·mg/L, at least 4.4 h·mg/L, at least 4.7 h·mg/L, at least 5 h·mg/L, at least 5.3 h·mg/L, at least 5.6 h·mg/L, at least 5.9 h·mg/L, at least 6.2 h·mg/L, at least 6.5 h·mg/L, at least 6.8 h·mg/L, at least 7.1 h·mg/L, at least 7.4 h·mg/L, at least 7.7 h·mg/L, at least 8.0 h·mg/L, at least 8.3 h·mg/L, at least 8.6 h·mg/L, at least 8.9 h·mg/L, at least 9.2 h·mg/L, at least 9.5 h·mg/L, at least 9.8 h·mg/L, at least 10.1 h·mg/L, at least 10.4 h·mg/L, at least 10.7 h·mg/L, at least 11.0 h·mg/L, at least 11.3 h·mg/L, at least 11.6 h·mg/L, at least 11.9 h·mg/L, at least 12.2 h·mg/L, at least 12.5 h·mg/L, at least 12.8 h·mg/L, at least 13.1 h·mg/L, at least 13.4 h·mg/L, at least 13.7 h·mg/L, at least 14 h·mg/L, at least 14.3 h·mg/L, at least 14.6 h·mg/L, at least 14.9 h·mg/L, at least 15.2 h·mg/L, or at least 15.5 h·mg/L.

20  
25  
30

In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 1.5 h·mg/L to about 15.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 1.5 h·mg/L to about 2.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 2.6 h·mg/L to about 5.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 5.6 h·mg/L to about 7.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 7.6 h·mg/L to about 11.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 10.5 h·mg/L to about 15.5 h·mg/L, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  of at least 2.0 h·mg/L, at least 2.3 h·mg/L, at least 2.6 h·mg/L, at least 2.9 h·mg/L, at least 3.2 h·mg/L, at least 3.5 h·mg/L, at least 3.8 h·mg/L, at least 4.1 h·mg/L, at least 4.4 h·mg/L, at least 4.7 h·mg/L, at least 5 h·mg/L, at least 5.3 h·mg/L, at least 5.6 h·mg/L, at least 5.9 h·mg/L, at least 6.2 h·mg/L, at least 6.5 h·mg/L, at least 6.8 h·mg/L, at least 7.1 h·mg/L, at least 7.4 h·mg/L, at least 7.7 h·mg/L, at least 8.0 h·mg/L, at least 8.3 h·mg/L, at least 8.6 h·mg/L, at least 8.9 h·mg/L, at least 9.2 h·mg/L, at least 9.5 h·mg/L, at least

9.8 h·mg/L, at least 10.1 h·mg/L, at least 10.4 h·mg/L, at least 10.7 h·mg/L, at least 11.0 h·mg/L, at least 11.3 h·mg/L, at least 11.6 h·mg/L, at least 11.9 h·mg/L, at least 12.2 h·mg/L, at least 12.5 h·mg/L, at least 12.8 h·mg/L, at least 13.1 h·mg/L, at least 13.4 h·mg/L, at least 13.7 h·mg/L, at least 14 h·mg/L, at least 14.3 h·mg/L, at least 14.6 h·mg/L, at least 14.9 h·mg/L, at least 15.2 h·mg/L, or at least 15.5 h·mg/L.

In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 1.5 hours to about 10.5 hours including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 1.6 hours to about 2.5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 2.6 hours to about 5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 5.1 hours to about 7.5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 7.6 hours to about 8.5 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  ranging from about 8.6 hours to about 10.6 hours, including all iterations of integers within the specified range. In another aspect, the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit a mean plasma monomethyl fumarate  $T_{\max}$  of at least 1.6 hours, at least 1.8 hours, at least 2 hours, at least 2.2 hours, at least 2.4 hours, at least 2.6 hours, at least 2.8 hours,

at least 3 hours, at least 3.2 hours, at least 3.4 hours, at least 3.6 hours, at least 3.8 hours, at least 4 hours, at least 4.2 hours, at least 4.4 hours, at least 4.6 hours, at least 4.8 hours, at least 5 hours, at least 5.2 hours, at least 5.4 hours, at least 5.6 hours, at least 5.8 hours, at least 6 hours, at least 6.2 hours, at least 6.4 hours, at least 6.6 hours, at least 6.8 hours, at least 7 hours, at least 7.2 hours, at least 7.4 hours, at least 7.6 hours, at least 7.8 hours, at least 8 hours, at least 8.2 hours, at least 8.4 hours, at least 8.6 hours, at least 8.8 hours, at least 9.0 hours, at least 9.2 hours, at least 9.4 hours, at least 9.6 hours, at least 9.8 hours, at least 10 hours, at least 10.2 hours, at least 10.4 hours, or at least 10.6 hours.

Another embodiment described herein is a pharmaceutical composition for treating, prophylaxis, or amelioration of general autoimmune or neurodegenerative disorders, comprising a fumarate ester, wherein the composition exhibits an in vitro dissolution rate (% dissolution per minute) at pH 6.8, as described herein in any one of Drawings 2–12.

Another embodiment described herein is a pharmaceutical composition for treating, prophylaxis, or amelioration of general autoimmune or neurodegenerative disorders, including but not limited to multiple sclerosis or psoriasis, comprising a fumarate ester, wherein the composition exhibits an in vitro dissolution rate comprising about 10% to about 80% dissolution after about 5 minutes to about 480 minutes at pH 6.8, including each integer within the specified ranges of dissolution and time. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 20 minutes to about 1080 minutes, including each integer with in the specified time range. In one aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 5 min, is about 50% after about 10 min, about 50% after about 20 min, about 50% after about 30 min, about 50% after about 40 min, about 50% after about 50 min, about 50% after about 60 min, about 50% after about 70 min, about 50% after about 80 min, about 50% after about 90 min, about 50% after about 120 min, about 50% after about 150 min, about 50% after about 180 min, about 50% after about 210 min, about 50% after about 240 min, about 50% after about 300 min, is about 50% after about 330 min, about 50% after about 360 min, is about 50% after about 390 min, about 50% after about 420 min, about 50% after about 480 min, about 50% after about 540 min, about 50% after about 600 min, about 50% after about 660 min, about 50% after about 720 min, about 50% after about 780 min, about 50% after about 840 min, about 50% after about 900 min, about 50% after about 960 min, or about 50% after 1080 min. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 0.5 hour, about 50% after about 1 hour, about



50% after about 2 hours, about 50% after about 3 hours, about 50% after about 4 hours, about 50% after about 5 hours, about 50% after about 6 hours, about 50% after about 7 hours, about 50% after about 8 hours, about 50% after about 9 hours, about 50% after about 10 hours, about 50% after about 11 hours, about 50% after about 12 hours, about 50% after about 13 hours, about 50% after about 14 hours, about 50% after about 15 hours, about 50% after about 16 hours, about 50% after about 17 hours, or about 50% after about 18 hours. In one aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 10 minutes. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 20 minutes. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 45 minutes. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 60 minutes. In one aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 120 minutes. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 180 minutes. In another aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 240 minutes. In one aspect, the in vitro dissolution rate at pH 6.8 is about 50% after about 480 minutes.

15 It will be readily apparent to one of ordinary skill in the relevant arts that suitable modifications and adaptations to the compositions, methods, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All of the various embodiments, aspects, and options disclosed  
20 herein can be combined in any and all variations or iterations. The scope of the compositions, formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The ratios of the mass of any component of any of the formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the  
25 formulation are hereby disclosed as if they were expressly disclosed. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.

**EXAMPLES**

## Example 1

## DMF Enteric Soft Capsule Fills

Based on results of dimethyl fumarate (DMF) solubility testing in various lipid or lipophilic vehicles (data not shown), two formulations were selected for further studies and encapsulated in enteric soft gelatin capsules: one having polyethylene glycol and one with medium chain mono- and diglycerides. Organic acids such as caprylic acid, lactic acid, or oleic acid, were incorporated into the matrix fill to prevent the hydrolysis of dimethyl fumarate and to retain enteric properties of the shell. Application batches of enteric soft capsules were prepared by rotary die encapsulation using the fill compositions shown in **Table 5**.

<b>Ingredient</b>	<b>Capmul<sup>®</sup> MCM Matrix (A413-A)</b>		<b>PEG Matrix (A413-B)</b>	
	<b>mg/capsule</b>	<b>% wt</b>	<b>mg/capsule</b>	<b>% wt</b>
Dimethyl Fumarate (PSD: 80 $\mu$ m)	240	32.0	240	32.0
Capmul <sup>®</sup> MCM	367.5	49.0		
PEG 400	—	—	382.5	51.0
Povidone K30	52.5	7.0	37.5	5.0
Tween <sup>®</sup> 80	75	10.0	75	10.0
Lactic acid	15	2.0	15	2.0
<b>TOTAL</b>	<b>750</b>	<b>100%</b>	<b>750</b>	<b>100%</b>

The enteric soft capsules comprising the matrix formulations shown in **Table 5** were subject to two-stage dissolution experiments in a USP Apparatus II (e.g., paddle method at 100 rpm). For these experiments, the capsule is introduced in to simulated gastric fluid, 0.1 N HCl, pH 1.2, for 2 hours. After 2 hours, the capsule is transferred to simulated intestinal fluid, phosphate buffer, pH 6.8. The results are shown in **Figure 2**. The results show that the capsules retain their enteric properties for at least 2 hours in simulated gastric fluid at pH 1.2. Both types of capsules released DMF shortly after being transferred to simulated intestinal fluid, pH 6.8. The enteric soft capsules comprising matrices comprising PEG 400 released DMF more rapidly than those comprising Capmul<sup>®</sup> MCM (ABITEC Corp.; medium chain mono- and di-glycerides).

## Example 2

## Stability of the Enteric Soft Capsules over Time

The temporal stability of the dimethyl fumarate enteric soft capsule fill formulation shown in **Table 6** was assessed. A sample of DMF enteric soft capsules was subjected to accelerated aging by a 1 month of exposure to 40 °C and 75% relative humidity conditions and then evaluated in two-stage dissolution experiment. A second sample of DMF enteric soft capsules was subject to two-stage dissolution shortly after manufacturing. Both sets of enteric capsules remained intact in the acidic conditions for at least 2 hours. **Figure 3**. The freshly manufactured capsules released DMF slightly faster than the age-accelerated capsules when the pH was shifted to 6.8 (phosphate buffer).

<b>Table 6. DMF Fill Composition</b>		
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate (PSD: 80 µm )	240	32.0
Capmul <sup>®</sup> MCM	367.5	49.0
Povidone K 30	52.5	7.0
Tween <sup>®</sup> 80	75	10.0
Lactic acid	15	2.0
<b>TOTAL</b>	<b>750 mg</b>	<b>100%</b>

## Example 3

## DMF Release in Enteric Soft Capsules

A developmental batch of enteric soft capsules comprising a Capmul<sup>®</sup> MCM matrix containing particles of dimethyl fumarate (**Table 6**) was subject to two-stage dissolution at pH 1.2 in simulated gastric fluid for 2 hours, then the buffer was changed to phosphate buffer, pH 6.8, containing 2% Cremophor<sup>®</sup> RH 40. **Figure 4**. The enteric capsules remained intact in the acidic condition, and then began releasing DMF within 20 minutes of the pH-shift to simulated intestinal fluid.

## Example 4

## Surfactants Affect DMF Release Rate

Enteric soft capsules were prepared with matrices comprising 10% Tween<sup>®</sup> 80 (Uniqema, ICI Americas Inc; polyoxyethylene (80) sorbitan monooleate; e.g., polysorbate 80) or 10% Cremophor<sup>®</sup> RH 40 (BASF SE; polyoxyl 40 hydrogenated castor oil) (Table 7) and then tested in dissolution experiments at pH 6.8. Figure 5. The enteric soft capsules with fills containing Cremophor<sup>®</sup> released DMF much more rapidly than those containing Tween<sup>®</sup> 80.

Ingredient	Tween <sup>®</sup> 80 Matrix		Cremophor <sup>®</sup> RH 40 Matrix	
	mg/capsule	% wt	mg/capsule	% wt
Dimethyl Fumarate (PSD: 80 μm)	240	32.0	240	32.0
Capmul <sup>®</sup> MCM	367.5	49.0	367.5	49.0
Povidone K 30	52.5	7.0	52.5	7.0
Tween <sup>®</sup> 80	75	10.0	—	—
Cremophor <sup>®</sup> RH 40	—	—	75	10.0
Lactic acid	15	2.0	15	2.0
<b>TOTAL</b>	<b>750</b>	<b>100%</b>	<b>750</b>	<b>100%</b>

## 10 Example 5

## Polyvinylpyrrolidone Concentration Affects DMF Release Rate

Enteric soft capsules prepared containing fills with of 3% or 5% concentrations of Povidone K30 (e.g., PVP; 30,000 MW) (Table 8) were tested in dissolution experiments at pH 6.8. Figure 6. The enteric soft capsules with matrices containing 5% Povidone K30 released DMF more rapidly at pH 6.8 than those with fills containing 3% Povidone K30.

Ingredient	3% PVP		5% PVP	
	mg/capsule	% wt	mg/capsule	% wt
Dimethyl Fumarate (PSD: 80 μm)	240	32.0	240	32.0
Capmul <sup>®</sup> MCM	397.5	53	382.5	51
Cremophor <sup>®</sup> RH 40	75	10.0	75	10.0
Povidone K 30	22.5	3.0	37.5	5.0
Lactic acid	15	2.0	15	2.0
<b>TOTAL</b>	<b>750</b>	<b>100%</b>	<b>750</b>	<b>100%</b>
<b>Viscosity:</b>	<b>43191 Cp</b>		<b>122000 Cp</b>	

Based on the foregoing formulation studies, the Capmul<sup>®</sup> MCM-based formulation was selected for further analysis. A batch was manufactured using the formulation below (**Table 9**).

<b>Table 9. DMF Fill Composition</b>		
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl Fumarate (PSD: 80 $\mu\text{m}$ )	240	32
Capmul <sup>®</sup> MCM	375	50
Cremophor <sup>®</sup> RH 40	75	10
Povidone K 30	52.5	7
Lactic acid	15	2
<b>TOTAL</b>	<b>750 mg</b>	<b>100%</b>

## 5 Example 6

DMF Enteric Soft Capsules are Amenable to Controlled or Extended Release

The release profile of DMF is modified by varying the enteric soft capsule shell composition or by altering the fill composition or particle size of the active ingredient. Three different release profiles were observed under two-stage dissolution experiments. All enteric soft capsules were resistant to acid for at least 2 hours, and begin releasing DMF upon transition to pH 6.8. **Figure 7**. A release profile was observed in an enteric soft capsule comprising a matrix of Capmul<sup>®</sup> MCM and Cremophor<sup>®</sup> RH 40 (**Table 10; Release Profile 1**). A different release profile was observed with an enteric soft capsule shell comprising a Capmul<sup>®</sup> MCM and Tween<sup>®</sup> 80 matrix (**Table 6; Release Profile 2**). Another release profile was observed with an enteric soft capsule shell comprising a matrix of soybean oil, Tween<sup>®</sup> 80, and solid particles of DMF having an average particle distribution size of 148  $\mu\text{m}$  (**Table 11; Release Profile 3**).

<b>Table 10. DMF Fill Composition (P31)</b>		
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate (PSD: 80 $\mu\text{m}$ )	240	32.0
Capmul <sup>®</sup> MCM	367.5	49.0
Cremophor <sup>®</sup> RH 40	75	10.0
Povidone K 30	52.5	7.0
Lactic acid	15	2.0
<b>TOTAL</b>	<b>750 mg</b>	<b>100%</b>

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate (PSD 148 $\mu\text{m}$ )	240	43.6
Soybean oil	285.25	51.9
Aerosil 200	75	10.0
Tween <sup>®</sup> 80	11	2.0
Caprylic acid	11	2.0
<b>TOTAL</b>	<b>550 mg</b>	<b>100%</b>

## Example 7

## DMF Particle Size Affects Release Rate

5 Enteric soft capsules comprising matrices with DMF particles of differing sizes were subject to dissolution at pH 6.8. **Figure 8.**

<b>Ingredient</b>	<b>Formulation</b>					
	<b>A (P7)</b>		<b>B (P8)</b>		<b>C (P9)</b>	
	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: 168 $\mu\text{m}$	240	43.6	—	—	—	—
DMF PSD: 148 $\mu\text{m}$	—	—	240	43.6	—	—
DMF PSD: 90 $\mu\text{m}$	—	—	—	—	240	43.6
PEG 400	244	44.4	244	44.4	244	44.4
Povidone K30	—	—	—	—	—	—
Tween <sup>®</sup> 80	55	10	55	10	55	10
Caprylic acid	11	2	11	2	11	2
Lactic acid	—	—	—	—	—	—
<b>TOTAL</b>	<b>550</b>	<b>100</b>	<b>550</b>	<b>100</b>	<b>550</b>	<b>100</b>
<b>Ingredient</b>	<b>Formulation</b>					
	<b>D (P25)</b>		<b>E (P15)</b>		<b>F (P23)</b>	
	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: 76 $\mu\text{m}$	240	34.3	—	—	—	—
DMF PSD: 26 $\mu\text{m}$	—	—	240	28.2	240	28.2
PEG 400	355	50.7	508	59.8	482	56.8
Povidone K30	21	3	—	—	26	3
Tween <sup>®</sup> 80	70	10	85	10	85	10
Caprylic acid	—	—	17	2	17	2
Lactic acid	14	2	—	—	—	—
<b>TOTAL</b>	<b>700</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>

## Example 8

Enteric soft capsules comprising various matrices comprising DMF particles having particle size distribution of  $d_{90} \leq 90 \mu\text{m}$  were prepared and analyzed in two stage (pH 1.2 and pH 6.8) or single stage (pH 6.8) dissolution experiments (data not shown). (Tables 13–15).

5

<b>Table 13. Various DMF Fill Compositions</b>						
	<b>Formulation</b>					
	<b>A (P32)</b>		<b>B (P33)</b>		<b>C (P34)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	32.0	240	32.0	240	32.0
Capmul <sup>®</sup> MCM	360	48.0	322.5	43.0	352.5	47.0
Cremophor <sup>®</sup> RH 40	112.5	15.0	150	20.0	112.5	15.0
Lactic acid	37.5	5.0	37.5	5.0	37.5	5.0
<b>TOTAL</b>	<b>750</b>	<b>100</b>	<b>750</b>	<b>100</b>	<b>750</b>	<b>100</b>
	<b>D (P35)</b>		<b>E (P37)</b>		<b>F (P38)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	32.0	240	32.0	240	32.0
Capmul <sup>®</sup> MCM	315	42.0	360	48.0	360	48.0
Cremophor <sup>®</sup> RH 40	150	20.0	75	10.0	75	10.0
Lactic acid	37.5	5.0	37.5	5.0	37.5	5.0
Povidone K 30	7.5	1.0	—	—	—	—
PEG 400	—	—	37.5	5.0	—	—
Polypropylene glycol	—	—	—	—	37.5	5.0
<b>TOTAL</b>	<b>750</b>	<b>100</b>	<b>750</b>	<b>100</b>	<b>750</b>	<b>100</b>
	<b>G (P39)</b>		<b>H (P41)</b>		<b>I (P43)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.2	240	28.2	240	28.2
Capmul <sup>®</sup> MCM	482.5	56.8	397.5	46.8	397.5	46.8
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.0	—	—
Lactic acid	42.5	5.0	42.5	5.0	42.5	5.0
Labrasol <sup>®</sup>	—	—	85	10.0	170	20.0
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>

<b>Table 14. Various DMF Fill Compositions</b>						
<b>Ingredient</b>	<b>Formulation</b>					
	<b>A (P44)</b>		<b>B (P45)</b>		<b>C (P46)</b>	
	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.2	240	28.2	240	28.2
Capmul <sup>®</sup> MCM	372	43.8	355	41.8	329.5	38.8
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.0	85	10.0
Lactic acid	42.5	5.0	42.5	5.0	42.5	5.0
Labrasol <sup>®</sup>	85	10.0	85	10.0	85	10.0
Povidone K 30	25.5	3.0	—	—	25.5	3.0
Mannitol	—	—	42.5	5.0	42.5	5.0
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>
<b>Ingredient</b>	<b>D (P47)</b>		<b>E (P48)</b>		<b>F (P49)</b>	
	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
	DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.2	240	28.2	240
Capmul <sup>®</sup> MCM	384.75	45.3	284.195	33.43	312.5	36.76
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.0	85	10.0
Lactic acid	42.5	5.0	42.5	5.0	42.5	5.0
Povidone K 30	12.75	1.5	—	—	—	—
Labrasol <sup>®</sup>	—	—	85	10.0	85	10.0
PEG 3350	85	10.0	113.305	13.33	85	10.00
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>
<b>Ingredient</b>	<b>G (P50)</b>		<b>H (P51)</b>		<b>I (P52)</b>	
	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
	DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.2	240	28.2	240
Capmul <sup>®</sup> MCM	333.75	39.26	287	33.76	333.75	39.26
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.00	85	10.00
Lactic acid	42.5	5.0	42.5	5.0	42.5	5.0
Labrasol <sup>®</sup>	85	10.0	85	10.0	85	10.00
PEG 3350	63.75	7.50	—	—	—	—
Povidone K 17	—	—	25.5	3.00	—	—
Mannitol	—	—	85	10.00	—	—
Crospovidone-CL	—	—	—	—	63.75	7.50
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>



<b>Table 15. Various DMF Fill Compositions</b>						
	<b>Formulation</b>					
	<b>A (P53)</b>		<b>B (P54)</b>		<b>C (P55)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.24	240	28.24	240	28.24
Capmul <sup>®</sup> MCM	397.5	46.76	397.5	46.76	390.7	45.96
Cremophor <sup>®</sup> RH 40	85	10.00	85	10.00	85	10.00
Lactic acid	42.5	5.00	42.5	5.00	42.5	5.00
PEG 3350	85	10.00	—	—	—	—
PEG 400	—	—	—	—	42.5	5.00
Lutrol <sup>®</sup> F 68	—	—	85	10.00	—	—
Sodium lauryl sulfate	—	—	—	—	49.3	5.80
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>
	<b>D (P56)</b>		<b>E (P57)</b>		<b>F (P58)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.24	240	28.24	240	28.24
Capmul <sup>®</sup> MCM	355	41.76	363.5	42.76	355	41.76
Cremophor <sup>®</sup> RH 40	85	10.00	85	10.00	85	10.00
Lactic acid	42.5	5.00	42.5	5.00	42.5	5.00
PEG 400	85	10.00	85	10.00	85	10.00
Crospovidone CL	42.5	5.00	—	—	—	—
Crospovidone CL-F	—	—	34	4.00	—	—
Crospovidone CL-M	—	—	—	—	42.5	5.00
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>
	<b>G (P59)</b>		<b>H (P60)</b>		<b>I (P61)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
DMF PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.24	240	28.24	240	28.24
Capmul <sup>®</sup> MCM	312.5	36.76	355	41.76	329.5	38.76
Cremophor <sup>®</sup> RH 40	85	10.00	85	10.00	85	10.00
Lactic acid	42.5	5.00	42.5	5.00	42.5	5.00
Labrasol <sup>®</sup>	85	10.00	85	10.00	85	10.00
Pearlitol <sup>®</sup> Flash	85	10.00	—	—	42.5	5.00
Croscarmellose Sodium	—	—	42.5	5.00	25.5	3.00
<b>TOTAL</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>	<b>850</b>	<b>100</b>

## Example 9

## Capsule Shell Thickness Affects Release Rate

Application batches of enteric soft capsules with shell thicknesses of 0.028 inches or 0.033 inches were prepared comprising DMF particles having particle size distribution of  $d_{90} \leq 90 \mu\text{m}$  in various matrices (**Table 16**) and analyzed in two stage (pH 1.2 and pH 6.8) dissolution experiments (**Figure 9**).

<b>Table 16. DMF Fill Composition s</b>				
	<b>A (APP021214)</b>		<b>B (APP020714)</b>	
	(0.028 inch ribbon)		(0.033 inch ribbon)	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% wt</b>	<b>mg/capsule</b>	<b>% wt</b>
Dimethyl Fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.2	240	28.2
Capmul <sup>®</sup> MCM	440	51.8	465.5	54.8
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.0
Povidone K30	42.5	5.0	42.5	5.0
PEG 400	—	—	42.5	5.0
Crospovidone-CL	17	2.0	—	—
<b>TOTAL</b>	<b>850</b>	<b>100%</b>	<b>850</b>	<b>100%</b>
	<b>C (APP022414-A)</b>		<b>D (APP022414-B)</b>	
	(0.028 inch ribbon)		(0.028 inch ribbon)	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% wt</b>	<b>mg/capsule</b>	<b>% wt</b>
Dimethyl Fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.24	240	28.24
Capmul <sup>®</sup> MCM	312.5	36.76	312.5	36.76
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.0
Povidone K30	42.5	5.0	42.5	5.0
PEG 600	127.5	15.0	—	—
Crospovidone-CL	42.5	5.0	—	—
Labrasol <sup>®</sup>	—	—	85	10.0
Pearlitol <sup>®</sup> Flash	—	—	85	10.0
<b>TOTAL</b>	<b>850</b>	<b>100%</b>	<b>850</b>	<b>100%</b>

## Example 10

A GMP batch of enteric soft capsules (0.038-inch shell thickness) comprising DMF particles having particle size distribution of PSD:  $d_{90} \leq 90 \mu\text{m}$  was prepared with the matrix composition shown in **Table 17** and analyzed in two stage (pH 1.2 and pH 6.8) dissolution experiments (**Figure 10**) and compared to application batches (**Table 15**).

<b>Table 17. GMP DMF Fill Composition</b>		
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	240	32.0
Capmul <sup>®</sup> MCM	375	50.0
Cremophor <sup>®</sup> RH 40	75	10.0
Povidone K 30	22.5	3.0
Lactic acid	37.5	5.0
<b>TOTAL</b>	<b>750 mg</b>	<b>100%</b>

## Example 11

Povidone K30 and PEG 600 affect DMF release rate

DMF matrices were prepared with and without Povidone K30 or PEG 600 (**Table 18**) and analyzed in single stage (pH 6.8) dissolution experiments (**Figure 11**).

5

<b>Table 18. DMF Fill Compositions</b>				
	<b>A (P62)</b>		<b>B (P63)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate PSD: d90 ≤ 90 μm	240	28.2	240	28.24
Capmul <sup>®</sup> MCM	482.5	56.8	384.75	45.26
Cremophor <sup>®</sup> RH 40	85	10.0	85	10.00
Povidone K 30	—	—	12.75	1.50
PEG 600	—	—	85	10.00
Lactic acid	42.5	5.0	42.5	5.0
<b>TOTAL</b>	<b>850 mg</b>	<b>100%</b>	<b>850 mg</b>	<b>100%</b>
	<b>C (P64)</b>		<b>D (P65)</b>	
<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate PSD: d90 ≤ 90 μm	240	28.24	240	28.24
Capmul <sup>®</sup> MCM	457	53.76	372	43.76
Cremophor <sup>®</sup> RH 40	85	10.00	85	10.00
Povidone K 30	25.5	3.00	25.5	3.00
PEG 600	—	—	85	10.00
Lactic acid	42.5	5.00	42.5	5.00
<b>TOTAL</b>	<b>850 mg</b>	<b>100%</b>	<b>850 mg</b>	<b>100%</b>

## Example 12

A batch of enteric soft capsules (0.038 inch shell thickness) comprising DMF particles having particle size distribution of PSD:  $d_{90} \leq 90 \mu\text{m}$  was prepared with the matrix composition shown in **Table 19** and analyzed in two stage (pH 1.2 and pH 6.8) dissolution experiments (Figure 12). This example provides a lower dose of DMF (120 mg) compared with that shown in **Table 6** (240 mg).

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	120	28.2
Capmul <sup>®</sup> MCM	228.5	53.8
Cremophor <sup>®</sup> RH 40	42.5	10.0
Povidone K 30	12.75	3.0
Lactic acid	21.25	5.0
<b>TOTAL</b>	<b>425 mg</b>	<b>100%</b>

## Example 13

A batch of enteric soft capsules (0.038 inch shell thickness) comprising monomethyl fumarate (MMF) particles having particle size distribution of PSD:  $d_{90} \leq 90 \mu\text{m}$  was prepared with the matrix composition shown in **Table 20**. This example provides MMF (240 mg).

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Monomethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	240	28.2
Capmul <sup>®</sup> MCM	457	53.8
Cremophor <sup>®</sup> RH 40	85	10.0
Povidone K 30	25.5	3.0
Lactic acid	42.5	5.0
<b>TOTAL</b>	<b>850 mg</b>	<b>100%</b>

Example 14

A batch of enteric soft capsules (0.038 inch shell thickness) comprising monomethyl fumarate (MMF) particles having particle size distribution of PSD:  $d_{90} \leq 90 \mu\text{m}$  can be prepared with the matrix composition shown in **Table 21**. This example provides MMF (480 mg).

5

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Monomethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	480	48–56.4
Capmul <sup>®</sup> MCM	216–470	25.5–47
Cremophor <sup>®</sup> RH 40	7.3–120	0.85–12
Povidone K 30	7.3–50	0.85–5
Lactic acid	21.7–50	2.55–5
<b>TOTAL</b>	<b>850 mg–1000 mg</b>	<b>100%</b>

Example 15

Enteric soft capsules comprising particles of dimethyl fumarate, monomethyl fumarate, or a combination thereof having particle size distribution of PSD:  $d_{90} \leq 90 \mu\text{m}$  can be prepared with an 850 mg matrix in the compositions shown in **Table 22**. This example provides DMF or MMF in a QD formulation (~480 mg).

10

<b>Ingredient</b>	<b>Percent Weight</b>					
	<b>EX1</b>	<b>EX2</b>	<b>EX3</b>	<b>EX4</b>	<b>EX5</b>	<b>EX6</b>
Dimethyl fumarate or Monomethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	56.4	56.4	56.4	56.4	56.4	56.4
Capmul <sup>®</sup> MCM	30.6	39.95	28.9	28.9	25.5	32.7
Cremophor <sup>®</sup> RH 40	8.5	0.85	8.5	8.5	10.2	6.1
Povidone K 30	0.85	0.85	2.55	2.55	4.25	1.8
Lactic acid	4.25	2.55	4.25	4.25	4.25	3.0
<b>TOTAL</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>

## Example 16

Enteric soft capsules comprising particles of dimethyl fumarate, monomethyl fumarate, or a combination thereof having particle size distribution of PSD:  $d_{90} \leq 90 \mu\text{m}$  can be prepared with a 1000 mg matrix in the compositions shown in **Table 23**. This example provides DMF or

5 MMF in a QD formulation (~480 mg).

<b>Table 23. DMF/MMF 1000 mg Fill Compositions</b>						
<b>Ingredient</b>	<b>Percent Weight</b>					
	<b>EX1</b>	<b>EX2</b>	<b>EX3</b>	<b>EX4</b>	<b>EX5</b>	<b>EX6</b>
Dimethyl fumarate or Monomethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	48	48	48	48	48	48
Capmul <sup>®</sup> MCM	44	36	47	34	34	38.9
Cremophor <sup>®</sup> RH 40	2	10	1	10	10	7.2
Povidone K 30	1	1	1	3	3	2.2
Lactic acid	5	5	3	5	5	3.6
<b>TOTAL</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>

## Example 17

## Stability of the Enteric Soft Capsules over Time

The temporal stability of the dimethyl fumarate enteric soft capsule pharmaceutical composition shown in **Table 24** was assessed under three ICH conditions. A sample of DMF enteric soft capsules was subject to chemical analysis and two-stage dissolution shortly after manufacturing ( $T_0$ ). Samples of DMF enteric soft capsules were subjected to Room Temperature Conditions (25 °C, 60% relative humidity) for 1 month, 2, months, 3 months, and 6 months. Other samples of DMF enteric soft capsules were subjected to Intermediate Conditions (30 °C, 65% relative humidity) for 1 month, 2 months, and 3 months. Additional samples of DMF enteric soft capsules were subjected to Accelerated Conditions (40 °C and 75% relative humidity) for 1 month and 2 months. After the designated incubation period, the capsules were chemically analyzed and evaluated in two-stage dissolution experiments at pH 1.2 and 6.8 as described herein if conditions permitted (i.e., non-leaking capsules). Two-stage dissolution results for DMS enteric soft capsules at  $T_0$ , and after 3- and 6-months at Room Temperature Conditions (25 °C, 60% RH) are shown in **Figure 13**.

<b>Ingredient</b>	<b>mg/capsule</b>	<b>% weight</b>
Dimethyl fumarate PSD: $d_{90} \leq 90 \mu\text{m}$	240	32.0
Capmul <sup>®</sup> MCM	375	50.0
Cremophor <sup>®</sup> RH 40	75	10.0
Povidone K 30	22.5	3.0
Lactic acid	37.5	5.0
<b>TOTAL</b>	<b>750 mg</b>	<b>100%</b>



<b>Table 25. GMP DMF Stability</b>					
	<b>Initial</b>	<b>25 °C, 60% Relative Humidity</b>			
	<b>T<sub>0</sub></b>	<b>1 M</b>	<b>2 M</b>	<b>3 M</b>	<b>6 M</b>
<b>Assay</b>	101.2%	101.0%	102.4%	101.25	98.8%
<b>Degradation Products</b>					
	<b>T<sub>0</sub></b>	<b>1 M</b>	<b>2 M</b>	<b>3 M</b>	<b>6 M</b>
Monomethyl Fumarate	0.14%	0.13%	0.14%	0.16%	0.18%
RRT 0.74	ND	ND	0.07%	0.09%	0.18%
RRT 1.61	0.05%	ND	ND	ND	ND
RRT 2.18	ND	ND	ND	<0.05%	0.09%
Total Degradation Products	0.19%	0.13%	0.21%	0.25%	0.45%
<b>30 °C, 65% Relative Humidity</b>					
	<b>1 M</b>	<b>2 M</b>	<b>3 M</b>	<b>40 °C, 75% Rel. Humid.</b>	
	<b>1 M</b>	<b>2 M</b>	<b>3 M</b>	<b>1 M</b>	<b>2 M</b>
<b>Assay</b>	100.1%	99.4%	99.5%	99.3	113.1*
<b>Degradation Products</b>					
	<b>1 M</b>	<b>2 M</b>	<b>3 M</b>	<b>1 M</b>	<b>2 M</b>
Monomethyl Fumarate	0.14%	0.17%	0.22%	0.22%	0.26%
RRT 0.74	0.14%	0.22%	0.28%	0.3%	0.46%
RRT 1.61	0.06%	0.11%	0.14%	0.15%	0.35%
RRT 2.18	0.34%	0.5%	0.64%	0.67%	1.07%
Total Degradation Products	0.14%	0.17%	0.22%	0.22%	0.26%
*Data was collected on fill extracted from leaking capsules. <i>Note:</i> Leaking capsules were observed at the 2- and 3-month time points for the accelerated condition (40 °C, 75% RH). This was expected for the enteric soft gelatin capsules. The intermediate condition (30 °C, 65% RH) and long-term condition (25 °C, 60%RH) will be assessed at the 12-month and 24-month time points to assess chemical stability.					

**CLAIMS**

What is claimed is:

1. An oral pharmaceutical composition comprising a controlled release formulation of a fumarate ester (FAE).
2. The composition of claim 1, wherein the pharmaceutical composition comprises a controlled release enteric soft capsule and matrix comprising a fumarate ester.
3. The composition of claim 2, wherein the matrix comprises a lipid or lipophilic vehicle, a neutralizing agent, excipients, and solid particles of FAE.
4. The composition of claim 3, wherein the lipid or lipophilic vehicle comprises polyethylene glycols, polyvinylpyrrolidones, oils, and surfactants.
5. The composition of claim 4, wherein the surfactant comprises polysorbate 80 or polyoxyl 40 hydrogenated castor oil.
6. The composition of claim 3, wherein the solid particles of FAE comprise milled or micronized particles.
7. The composition of claim 3, wherein the solid particles of FAE comprise average particle distribution sizes of about 20  $\mu\text{m}$  to about 300  $\mu\text{m}$ .
8. The composition of claim 3, wherein the solid particles of FAE comprise average particle distribution sizes of about 68  $\mu\text{m}$  to about 261  $\mu\text{m}$ .
9. The composition of claim 3, wherein the solid particles of FAE comprise average particle distribution sizes of about 80  $\mu\text{m}$  to about 261  $\mu\text{m}$ .

10. The composition of claim 3, wherein the neutralizing agent comprises an organic acid, ester, or salt.
11. The composition of claim 10, wherein the organic acid comprises at least one of lactate, fumarate, caprylate, caprate, oleate, maleate, succinate, tartrate, citrate, glutamate, gluconate, or esters or salts thereof, or combinations thereof.
12. The composition of any one of claims 1–11, wherein the matrix comprises solid particles of FAE, a mixture of mono- and di-glycerides, polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid.
13. The composition of any one of claims 1–12, where in the matrix comprises:  
about 28–32% FAE (PSD 80  $\mu\text{m}$ );  
about 50–54% of a mixture of mono- and di-glycerides;  
at least about 1–10% polyvinylpyrrolidone;  
at least about 2–10% polyoxyl 40 hydrogenated castor oil, and  
at least about 1–5% lactic acid.
14. The composition of any one of claims 1–13, wherein the composition has controlled release, delayed release, or extended release properties.
15. The composition of any one of claims 1–13, further comprising one or more non-steroidal anti-inflammatory drugs.
16. The composition of any one of claims 1–13, wherein the composition prevents sublimation of FAE during manufacturing.
17. The composition of any one of claims 1–13, wherein the composition reduces the onset of any flushing side effects.

18. The composition of any one of claims 1–13, wherein the composition reduces the onset of any gastrointestinal side effects.
19. The composition of any one of claims 1–18, wherein the composition is stable for at least 1 year at 25 °C.
20. The composition of any one of claims 2–19, wherein the enteric soft capsule shell comprises an acid-insoluble polymer, a film forming polymer, a plasticizer, an alkaline neutralizing agent, a solvent, optionally, a coloring agent, a flavoring or a pharmaceutical excipient.
21. The composition of claim 20, wherein the enteric soft capsule shell comprises:
  - about 30% of at least one film-forming polymer;
  - about 10% of at least one enteric, acid-insoluble polymer;
  - about 20% of at least one plasticizer;
  - about 1% of at least one alkali-neutralizing agent;
  - about 37% of a solvent;
  - about 1.5% of an opacifying agent; and
  - optionally, at least one coloring agent.
22. The composition of any one of claims 2–21, wherein the enteric soft capsule shell comprises gelatin, acrylic methacrylate copolymers, glycerol, triethyl citrate, ammonia, water, and titanium dioxide.
23. A method for manufacturing an oral enteric soft capsule shell and matrix comprising a fumarate ester comprising
  - (i) providing a matrix fill comprising the composition of any one of claims 2–19;
  - (ii) providing an enteric soft capsule shell comprising the composition of any one of claims 20–22;
  - (iii) casting the enteric soft capsule shell into films using heat-controlled drums or surfaces; and

- (iv) forming an enteric soft capsule comprising the matrix fill composition using rotary die encapsulation technology.
24. The enteric soft capsule comprising a fumarate ester matrix produced by the method of claim 23.
25. An enteric soft capsule comprising a matrix fills comprising a fumarate ester, wherein the matrix comprises:
- about 28–32% fumarate ester (PSD 80  $\mu\text{m}$ );
  - about 50–54% a mixture of mono- and di-glycerides;
  - at least about 1–7% polyvinylpyrrolidone;
  - at least about 2–10% polyoxyl 40 hydrogenated castor oil, and
  - at least about 1–5% lactic acid;
- and
- wherein the enteric soft capsule shell comprises:
- about 30% gelatin;
  - about 10% methylacrylic acid copolymer;
  - about 18% glycerol;
  - about 1 % triethyl citrate;
  - about 1.5% ammonia;
  - about 37% water; and
  - about 1.5% titanium dioxide.
26. The enteric soft capsule of any one of claims 24–25, wherein the capsule is resistant to dissolution at about pH 1.2 for at least about 2 hours.
27. The enteric soft capsule of any one of claims 24–26, wherein the capsule begins dissolution at pH of about 6.8 within about 10 min.
28. The enteric soft capsule of any one of claims 24–27, wherein the capsule has immediate release, controlled release, delayed release, or extended release properties.

29. The enteric soft capsule of any one of claims 24–28, wherein the enteric soft capsule reduces the onset or the symptoms of any gastrointestinal side effects.
30. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising administering to a subject in need thereof an oral pharmaceutical composition comprising a controlled release formulation of a fumarate ester, wherein the subject achieves a reduction of annualized relapse rate relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea.
31. The method of claim 30, wherein the pharmaceutical composition comprises the composition of any one of claims 1–22.
32. The method of claim 30, wherein the pharmaceutical composition comprises the enteric soft capsule of any one of claims 24–29.
33. A pharmaceutical composition according to any one of claims 1–22 or 24–29, useful for treating neurodegenerative disorders.
34. The pharmaceutical composition according to claim 33, wherein the neurodegenerative disorder is multiple sclerosis or psoriasis.
35. The pharmaceutical composition according to claim 33, wherein subjects that are administered the composition exhibit a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 3.5 hours.
36. A pharmaceutical composition according to any one of claims 1–22, 24–29, or 33–35, useful for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative

disorders, including but not limited to, acute dermatitis, adrenal leukodystrophy, AGE-induced genome damage, Alexander's disease, alopecia areata (totalis and universalis), Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, arthritis, asthma, autoimmune diseases, balo concentric sclerosis, Behçet's syndrome, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular insufficiency, central nervous system vasculitis, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic active (lupoid) hepatitis, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease and cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, diabetic retinopathy, fibromyalgia, graft versus host disease, granuloma annulare, granulomas including annulare, Grave's disease, Hashimoto's thyroiditis, hepatitis C viral infection, herpes simplex viral infection, human immunodeficiency viral infection, Huntington's disease, inflammatory bowel disease, irritable bowel disorder, ischemia, juvenile-onset diabetes mellitus, Krabbe disease, lichen planus, macular degeneration, mitochondrial encephalomyopathy, monomelic amyotrophy, multiple sclerosis (MS), myocardial infarction, necrobiosis lipoidica, neurodegeneration with brain iron accumulation, neurodermatitis, neuromyelitis optica, neuropathic pain, neurosarcoidosis, NF- $\kappa$ B mediated diseases, optic neuritis, organ transplantation rejection, paraneoplastic syndromes, Parkinson's disease, Pelizaeus-Merzbacher disease, pemphigus, pernicious anemia, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, radicular pain, radiculopathic pain, reperfusion injury, retinopathic pigmentosa, rheumatoid arthritis (RA), sarcoidosis, Schilder's disease, sciatic pain, sciatica, Sjögren's syndrome, subacute necrotizing myelopathy, such as polyarthritis, Susac's syndrome, systemic lupus erythematosus (SLE), tumors, transverse myelitis, ulcerative colitis, or Zellweger syndrome.

37. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to, acute dermatitis, adrenal leukodystrophy, AGE-induced genome damage, Alexander's disease, alopecia areata (totalis and universalis),

Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, arthritis, asthma, autoimmune diseases, balo concentric sclerosis, Behçet's syndrome, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular insufficiency, central nervous system vasculitis, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic active (lupoid) hepatitis, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease and cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, diabetic retinopathy, fibromyalgia, graft versus host disease, granuloma annulare, granulomas including annulare, Grave's disease, Hashimoto's thyroiditis, hepatitis C viral infection, herpes simplex viral infection, human immunodeficiency viral infection, Huntington's disease, inflammatory bowel disease, irritable bowel disorder, ischemia, juvenile-onset diabetes mellitus, Krabbe disease, lichen planus, macular degeneration, mitochondrial encephalomyopathy, monomelic amyotrophy, multiple sclerosis (MS), myocardial infarction, necrobiosis lipoidica, neurodegeneration with brain iron accumulation, neurodermatitis, neuromyelitis optica, neuropathic pain, neurosarcoidosis, NF- $\kappa$ B mediated diseases, optic neuritis, organ transplantation rejection, paraneoplastic syndromes, Parkinson's disease, Pelizaeus-Merzbacher disease, pemphigus, pernicious anemia, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, radicular pain, radiculopathic pain, reperfusion injury, retinopathic pigmentosa, rheumatoid arthritis (RA), sarcoidosis, Schilder's disease, sciatic pain, sciatica, Sjögren's syndrome, subacute necrotizing myelopathy, such as polyarthritis, Susac's syndrome, systemic lupus erythematosus (SLE), tumors, transverse myelitis, ulcerative colitis, or Zellweger syndrome, comprising administering to a subject in need thereof an oral pharmaceutical composition comprising a controlled release formulation of a fumarate ester, wherein the subject achieves a reduction of symptoms relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea.

38. The method of claim 37, wherein the pharmaceutical composition comprises the composition of any one of claims 1–22, 24–29, or 33–36.



39. The method of claim 37, wherein the pharmaceutical composition comprises the enteric soft capsule of any one of claims 24–29.
40. An oral pharmaceutical composition comprising an immediate release, delayed release, controlled release, or extended release formulation of a fumarate ester.
41. The composition of claim 40, wherein the composition comprises the composition of any one of claims 1–22, 24–29, or 33–36.
42. The composition of claim 40 or 41, wherein the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form twice-daily exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 2.41 mg/L and (b) a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 4.81 h·mg/L to about 11.2 h·mg/L.
43. The composition of claim 40 or 41, wherein the composition is provided in a dosage form containing a total amount of about 240 mg of a fumarate ester, wherein subjects administered the dosage form exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 3.4 mg/L, (b) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12\text{h}}$  ranging from about 2.4 h·mg/L to about 5.5 h·mg/L, and (c) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 5.6 h·mg/L.
44. The composition of claim 43, wherein the fumarate ester formulation is encapsulated in an enteric soft capsule.
45. The composition of claim 44, wherein the capsule contains a total amount of about 240 mg of a fumarate ester, wherein subjects administered the capsule exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 3.5 hours; (b) a mean plasma

- monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 3.4 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 5.5 h·mg/L; and (d) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 5.6 h·mg/L.
46. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any one of the compositions of claims 1–22, 24–29, 33–36, or 40–45, and a therapeutically amount of one or more non-steroidal anti-inflammatory drugs effective to reduce flushing.
47. The method of claim 46, wherein the one of more non-steroidal anti-inflammatory drug is aspirin, ibuprofen, naproxene, diclofenac, ketoprofen, celecoxib, or a combination thereof.
48. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising administering to a subject in need thereof any one of the compositions of claims 1–22, 24–29, 33–36, or 40–45, containing a compound, or a pharmaceutically acceptable salt thereof, that metabolizes to monomethyl fumarate wherein said administering the composition provides one or more of the following pharmacokinetic parameters: (a) a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 3.5 hours; (b) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 3.4 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{\text{overall}}$  ranging from about 4.81 h·mg/L to about 11.2 h·mg/L; (d) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 5.5 h·mg/L; and (e) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 5.6 h·mg/L.

49. A once daily oral pharmaceutical composition comprising a delayed release, controlled release, or extended release formulation of a fumarate ester.
50. The composition of claim 49, wherein the composition comprises the composition of any one of claims 1–22, 24–29, 33–36, or 40–45.
51. The composition of claim 49 or 50, wherein the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form once daily exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.03 mg/L to about 5.2 mg/L and (b) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L.
52. The composition of claim 49 or 50, wherein the composition is provided in a dosage form containing a total amount of about 480 mg of a fumarate ester, wherein subjects administered the dosage form exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 5.2 mg/L, (b) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 13.5 h·mg/L, and (c) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L.
53. The composition of claim 52, wherein the fumarate ester formulation is encapsulated in an enteric soft capsule.
54. The composition of claim 53, wherein the capsule contains a total amount of about 480 mg of a fumarate ester, wherein subjects administered the capsule exhibit one or more pharmacokinetic parameters selected from the group consisting of (a) a mean plasma monomethyl fumarate  $T_{\max}$  of from about 1.5 hours to about 10.5 hours; (b) a mean plasma monomethyl fumarate  $C_{\max}$  ranging from about 1.5 mg/L to about 5.2 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about

- 13.5 h·mg/L; and (d) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L.
55. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54, and a therapeutically amount of one or more non-steroidal anti-inflammatory drugs effective to reduce flushing.
56. The method of claim 55, wherein the one of more non-steroidal anti-inflammatory drug is aspirin, ibuprofen, naproxene, diclofenac, ketoprofen, celecoxib, or a combination thereof.
57. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising administering to a subject in need thereof any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 containing a compound, or a pharmaceutically acceptable salt thereof, that metabolizes to monomethyl fumarate wherein said administering the composition provides one or more of the following pharmacokinetic parameters: (a) a mean plasma monomethyl fumarate  $T_{max}$  of from about 1.5 hours to about 10.5 hours; (b) a mean plasma monomethyl fumarate  $C_{max}$  ranging from about 1.03 mg/L to about 5.2 mg/L; (c) a mean plasma monomethyl fumarate  $AUC_{0 \rightarrow 12h}$  ranging from about 2.4 h·mg/L to about 13.5 h·mg/L; and (d) a mean  $AUC_{0 \rightarrow \infty}$  ranging from about 2.4 h·mg/L to about 15.5 h·mg/L.
58. A pharmaceutical composition comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 for administration to a subject having multiple sclerosis, comprising a therapeutically effective amount of one or more fumarate esters, wherein

the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.

59. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of multiple sclerosis, the method comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 to a subject with multiple sclerosis, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.
60. A pharmaceutical composition comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 for administration to a subject having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis, comprising a therapeutically effective amount of one or more fumarate esters, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject; and wherein the administration does not require titration of the pharmaceutical composition.
61. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis, the method comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any one of the pharmaceutical compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 to a subject in need thereof, wherein the administration is sufficient to achieve a reduction of about 0.224 annualized relapse rate relative to baseline in the subject without substantially inducing one or more of flushing, abdominal pain, diarrhea,

- and nausea in the subject; and wherein the administration does not require titration of the pharmaceutical composition.
62. The method of claim 59 or 61, wherein the subject experiences one or more of flushing, abdominal pain, diarrhea, and nausea at a rate of less than about 10%.
63. The method of claim 59 or 61, wherein the subject is a child.
64. A pharmaceutical composition comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 for administration to a subject having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising a therapeutically effective amount of one or more fumarate esters, wherein the subject achieves a reduction of annualized relapse rate relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea.
65. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, the method comprising the administration of a therapeutically effective amount of one or more fumarate esters comprising any one of the pharmaceutical compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 to a subject in need thereof, wherein the subject achieves a reduction of annualized relapse rate relative to baseline without substantially experiencing one or more of flushing, abdominal pain, diarrhea, and nausea.
66. The composition of claim 65, wherein the subject is a child.
67. A pharmaceutical composition comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 for administration to a subject having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising a therapeutically effective amount of one or more fumarate

esters, wherein the pharmaceutical composition is stable at 25 °C 60% RH for at least 1 year.


68. A pharmaceutical composition comprising any one of the compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 for administration to a subject of less than 17 years of age having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising a therapeutically effective amount of one or more fumarate esters.
69. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a subject of less than 17 years of age having a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof having an age less than 17 a therapeutically effective amount of a fumarate ester comprising any one of the pharmaceutical compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54.
70. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorder, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any one of the pharmaceutical compositions of claims 1–22, 24–29, 33–36, 40–45, or 49–54 and a therapeutically amount of a leukotriene receptor antagonist.
71. The method of claim 70, wherein the leukotriene receptor antagonist comprises montelukast or zafirlukast.
72. A pharmaceutical composition comprising a soft capsule and a fill comprising any one of the formulations shown in Tables 1, 2, and 5–23.

73. A pharmaceutical composition for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to multiple sclerosis or psoriasis, comprising a fumarate ester, wherein the pharmaceutical composition exhibits an in vitro dissolution rate (% dissolution per minute) at pH 6.8, as shown in any one of the Drawings 2–12 herein.
74. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the pharmaceutical compositions described herein, wherein the pharmaceutical composition exhibits an in vitro dissolution rate (% dissolution per minute) at pH 6.8, as shown in any of Drawings 2–12 described herein.
75. A pharmaceutical composition for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a general autoimmune or neurodegenerative disorders, including but not limited to multiple sclerosis or psoriasis, comprising a fumarate ester, wherein the pharmaceutical composition exhibits an in vitro dissolution rate at pH 6.8 comprising about 10% to about 80% dissolution after about 10 minutes to about 480 minutes.
76. A method for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, including but not limited to multiple sclerosis or psoriasis, comprising orally administering to a subject in need thereof a therapeutically effective amount of a fumarate ester comprising any of the pharmaceutical compositions described herein, wherein the pharmaceutical composition is administered without titration of the pharmaceutical composition and without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.



77. A pharmaceutical composition for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of general autoimmune or neurodegenerative disorders, comprising a fumarate ester, wherein the pharmaceutical composition is administered without titration of the pharmaceutical composition and without substantially inducing one or more of flushing, abdominal pain, diarrhea, and nausea in the subject.

FIGURE 1



5

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7






FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12





FIGURE 13



5

**A. CLASSIFICATION OF SUBJECT MATTER**

**A61K 9/52(2006.01)i, A61K 47/44(2006.01)i, A61P 25/00(2006.01)i, A61K 31/145(2006.01)i, A61K 31/19(2006.01)i, A61K 31/192(2006.01)i, A61K 31/196(2006.01)i, A61K 31/21(2006.01)i, A61K 31/60(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K 9/52; A61K 31/22; A61K 9/64; A61K 31/22; A61K 45/06; A61K 31/223; A61K 31/225; A61K 9/20; A61K 47/44; A61P 25/00; A61K 31/145; A61K 31/19; A61K 31/192; A61K 31/196; A61K 31/21; A61K 31/60

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models  
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: fumarate ester, controlled release, soft capsule, enteric coating, dissolution rate, side effect

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2009-0304790 A1 (NILSSON, H. et al.) 10 December 2009 See paragraphs [0012], [0025], [0044], [0045], [0111] and [0113]; claims 3, 30, 31, 43 and 44; and figure 1.	1-12, 40, 49, 72, 73, 75, 77
Y		25
Y	US 2006-0165778 A1 (HASSAN, E. M. et al.) 27 July 2006 See paragraphs [0012]-[0015]; and claim 20.	25
A	US 7320999 B2 (JOSHI, R. K. et al.) 22 January 2008 See abstract; columns 6 and 7; and claims 1-18.	1-12, 25, 40, 49, 72, 73, 75, 77
A	US 2013-0259906 A1 (FORWARD PHARMA A/S) 03 October 2013 See the whole document.	1-12, 25, 40, 49, 72, 73, 75, 77
A	US 2013-0216615 A1 (GOLDMAN, D.) 22 August 2013 See the whole document.	1-12, 25, 40, 49, 72, 73, 75, 77

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 May 2015 (29.05.2015)

Date of mailing of the international search report

**29 May 2015 (29.05.2015)**

Name and mailing address of the ISA/KR

International Application Division  
Korean Intellectual Property Office  
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan City, 302-701,  
Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

LEE, Jeong A

Telephone No. +82-42-481-8740



**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 30-32, 37-39, 46-48, 55-57, 59, 61-63, 65, 69-71, 74, 76  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims 30-32, 37-39, 46-48, 55-57, 59, 61-63, 65, 69-71, 74 and 76 pertain to methods for treatment of the human body by surgery or therapy, as well as diagnostic methods practiced on the human body, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2.  Claims Nos.: 21, 24, 34, 35, 44, 45, 47, 53, 54, 56, 66, 71, 74  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
See the Extra Sheet.
3.  Claims Nos.: 13-20, 22, 23, 26-29, 31-33, 36, 38, 39, 41-43, 46, 48, 50-52, 55, 57-65, 67-70  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
  
  
  
  
  
  
  
  
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.



Continuation of: Box No. II. 2.

1) Claims 21, 24, 34, 35, 44, 45, 47, 53, 54, 56, 66 and 71 refer to one of claims which are not drafted in accordance with PCT Rule 6.4(a).

2) Claim 66 is directed to “a composition”, but claim 65 to which claim 66 refers claims “a method”.

3) Claim 74 uses a vague expression “any of the pharmaceutical compositions described herein”, thereby rendering the definition of the subject matter of said claim unclear.

Therefore, claims 21, 24, 34, 35, 44, 45, 47, 53, 54, 56, 66, 71 and 74 are so unclear that no opinion could be formulated as to novelty or inventive step, contrary to the requirement of PCT Article 6.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2015/017893**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2009-0304790 A1	10/12/2009	CN 101056624 A	17/10/2007
		CN 101304732 A	12/11/2008
		DK 2316430 T3	23/07/2012
		EP 1799196 A2	27/06/2007
		EP 1940382 A2	09/07/2008
		EP 1951206 A1	06/08/2008
		EP 2316430 A1	04/05/2011
		EP 2316430 B1	06/06/2012
		EP 2316430 B8	11/07/2012
		EP 2801354 A1	12/11/2014
		EP 2801355 A1	12/11/2014
		ES 2387192 T3	17/09/2012
		JP 2008-515822 A	15/05/2008
		JP 2009-510137 A	12/03/2009
		JP 2013-064007 A	11/04/2013
		PL 2316430 T3	30/11/2012
		PT 2316430 E	26/06/2012
		SI 2316430 T1	28/09/2012
		US 2008-0299196 A1	04/12/2008
		US 2008-0300217 A1	04/12/2008
		US 2013-0315993 A1	28/11/2013
		US 2013-0316003 A1	28/11/2013
		US 2014-0037720 A1	06/02/2014
		US 2014-0037740 A1	06/02/2014
		US 2014-0099364 A2	10/04/2014
		US 2014-0193495 A1	10/07/2014
		US 2014-0199386 A1	17/07/2014
		US 2014-0199387 A1	17/07/2014
		US 2014-0199388 A1	17/07/2014
		US 2014-0199390 A1	17/07/2014
		US 2014-0199392 A1	17/07/2014
		US 2014-0199393 A1	17/07/2014
		US 2014-0200272 A1	17/07/2014
		US 2014-0200273 A1	17/07/2014
		US 2014-0205659 A1	24/07/2014
		WO 2006-037342 A2	13/04/2006
		WO 2006-037342 A3	20/07/2006
		WO 2007-042034 A1	19/04/2007
		WO 2007-042035 A2	19/04/2007
		WO 2007-042035 A3	14/06/2007
US 2006-0165778 A1	27/07/2006	AU 2003-299191 A1	23/04/2004
		CA 2500663 A1	15/04/2004
		CA 2500663 C	28/05/2013
		CN 1688294 A	26/10/2005
		DK 1545475 T3	28/07/2014
		EP 1545475 A1	29/06/2005
		EP 1545475 B1	16/07/2014
EP 2772250 A1	03/09/2014		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2015/017893**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		ES 2500316 T3	30/09/2014
		JP 2006-505542 A	16/02/2006
		PT 1545475 E	16/09/2014
		SI 1545475 T1	30/10/2014
		US 2014-348879 A1	27/11/2014
		US 8685445 B2	01/04/2014
		WO 2004-030658 A1	15/04/2004
US 7320999 B2	22/01/2008	AT 242633 T	15/06/2003
		AU 1157200 A	13/06/2000
		AU 2000-11572 A1	13/06/2000
		AU 2000-11572 B2	26/09/2002
		AU 752733 B2	26/09/2002
		BG 105396 A	31/12/2001
		BG 64837 B1	30/06/2006
		BR 9914606 A	03/07/2001
		CA 2346438 A1	02/06/2000
		CA 2346438 C	03/10/2006
		CN 1182844 C	05/01/2005
		CN 1325302 A	05/12/2001
		CN 1615839 A	18/05/2005
		CZ 20010939 A3	15/05/2002
		CZ 299409 B6	16/07/2008
		DE 19853487 A1	25/05/2000
		DE 59905954 D1	17/07/2003
		DK 1131065 T3	25/08/2003
		EE 04389 B1	15/12/2004
		EE 200100266 A	16/12/2002
		EP 1131065 A2	12/09/2001
		EP 1131065 B1	11/06/2003
		ES 2195664 T3	01/12/2003
		HK 1042242 A1	19/08/2005
		HU 0103182 A2	28/01/2002
		IL 142728 A	10/12/2006
		IL 142728 D0	10/03/2002
		JP 2002-530324 A	17/09/2002
		JP 2005-097323 A	14/04/2005
		JP 2009-256384 A	05/11/2009
		JP 2012-255020 A	27/12/2012
		LU 92488 I2	15/01/2015
		NO 20011242 A	18/05/2001
		NO 20121479 A	18/05/2001
		NO 333257 B1	22/04/2013
		NZ 510247 A	31/10/2003
		PL 205948 B1	30/06/2010
		PL 348147 A1	06/05/2002
		RS 49995 B	29/09/2008
		RU 2215524 C2	10/11/2003
		SK 285601 B6	05/04/2007
		SK 5762001 A3	05/03/2002

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

**PCT/US2015/017893**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		TR 200101204 T2	21/09/2001
		US 2003-0018072 A1	23/01/2003
		US 2003-0184104 A1	02/10/2003
		US 2007-0248662 A1	25/10/2007
		US 2007-0248663 A1	25/10/2007
		US 2009-0181085 A1	16/07/2009
		US 2009-0182047 A1	16/07/2009
		US 2011-0293711 A1	01/12/2011
		US 2013-0004526 A1	03/01/2013
		US 2014-066505 A1	06/03/2014
		US 6509376 B1	21/01/2003
		US 7612110 B2	03/11/2009
		US 7619001 B2	17/11/2009
		US 7803840 B2	28/09/2010
		US 7915310 B2	29/03/2011
		US 8524773 B2	03/09/2013
		US 8759393 B2	24/06/2014
		WO 00-30622 A2	02/06/2000
		WO 00-30622 A3	02/11/2000
		YU 29901 A	30/04/2003
		ZA 200202335 A	27/08/2003
US 2013-0259906 A1	03/10/2013	CN 102369000 A	07/03/2012
		EP 2379062 A1	26/10/2011
		JP 2012-514623 A	28/06/2012
		US 2012-0034274 A1	09/02/2012
		WO 2010-079221 A1	15/07/2010
US 2013-0216615 A1	22/08/2013	AR 089931 A1	01/10/2014
		AU 2013-203445 A1	22/08/2013
		CA 2862885 A1	15/08/2013
		CN 104220061 A	17/12/2014
		CO 7141407 A2	12/12/2014
		EA 201491484 A1	27/02/2015
		EP 2811994 A1	17/12/2014
		IL 233833 D0	30/09/2014
		JP 2015-506377 A	02/03/2015
		KR 10-2015-0001726 A	06/01/2015
		MX 2014009469 A	22/09/2014
		PH 12014501750 A1	10/11/2014
		TW 201345520 A	16/11/2013
		US 2013-295169 A1	07/11/2013
		WO 2013-119677 A1	15/08/2013